Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Otorhinolaryngology

Free Subscription Articles published in Oral Oncol Retrieve available abstracts of 628 articles: HTML format

Single Articles

October 2026
1. XIE Y, Lin Y, He J, Ji Y, et al
   Mechanism study on CSF3-Induced M2 polarization of tumor-associated macrophages and CCL9 secretion in promoting tumor progression in head and neck squamous cell carcinoma.
   Oral Oncol. 2026;183:108176.
   PubMed     Abstract available
   
   
   
2. ROUSSEL LM, Berghian A, Hapdey S, Clatot F, et al
   The 5-mm margin in head and neck cancer surgery: From uncontrolled historical dogma to personalised surgery.
   Oral Oncol. 2026;182:108194.
   PubMed     Abstract available
   
   
   
3. NEH H, MacRae DC, de Vette SPM, van der Hoek L, et al
   Predicting taste alteration in head and neck cancer patients using 3D transformer-based deep learning model.
   Oral Oncol. 2026;182:108192.
   PubMed     Abstract available
   
   
   
4. KARPAGAVALLI G, Prakash IA, Ariyalakshmi B, Regina PF, et al
   Comment on "Does discharge location following head and neck cancer surgery affect quality outcomes?".
   Oral Oncol. 2026;182:108182.
   PubMed    
   
   
   
5. LONG CQ
   Does osteosarcopenia add prognostic information beyond osteopenia alone in head and neck cancer?
   Oral Oncol. 2026;182:108190.
   PubMed    
   
   
   
6. GUPTA K, Popat S, Sarin D
   Oncological and quality-of-life outcomes after robotic versus open neck dissection in oral cavity cancer: a prospective matched-pair analysis.
   Oral Oncol. 2026;182:108185.
   PubMed     Abstract available
   
   
   
7. LI SH
   Does nodal burden Truly Modify the prognostic effect of extranodal extension in oral Cancer?
   Oral Oncol. 2026;182:108177.
   PubMed    
   
   
   
8. YE T
   Separating rurality from population composition and subsite coding in head and neck cancer mortality trends.
   Oral Oncol. 2026;182:108179.
   PubMed    
   
   
   
9. LECHIEN JR, Vaira LA, Baudouin R, Guarino P, et al
   Transoral robotic versus laser surgery for cT1-T3 supraglottic laryngeal cancers: a systematic review and meta-analysis of comparative and non-comparative studies.
   Oral Oncol. 2026;182:108172.
   PubMed     Abstract available
   
   
   
10. SUZUKI K, Ueki Y, Ohno Y, Ohshima S, et al
    Prognostic significance and predictors of pathological response following neoadjuvant paclitaxel, carboplatin, and cetuximab therapy in head and neck squamous cell carcinoma.
    Oral Oncol. 2026;182:108175.
    PubMed     Abstract available
    
    
    
11. SASAKI AT, Boe LA, Eagan A, Patel SG, et al
    Differential associations between treatment delay and survival across head and neck cancer subsites: a national hospital-based framework for risk-stratified prioritization.
    Oral Oncol. 2026;182:108168.
    PubMed     Abstract available
    
    
    
12. SANABRIA A, Simo R, Cohen O, Kowalski LP, et al
    Neoadjuvant treatment or chemoselection in head and neck carcinoma. What makes one term different from another.
    Oral Oncol. 2026;182:108167.
    PubMed    
    
    
    
13. WU L, He J, Zhou Z, Luo R, et al
    Concurrent Versus Sequential PD-1 Blockade With Locoregional Radiotherapy After Chemoimmunotherapy in De Novo Metastatic Nasopharyngeal Carcinoma: A Landmark Analysis.
    Oral Oncol. 2026;182:108164.
    PubMed     Abstract available
    
    
    
14. ALI S, Mohammed MES, Yousif M, Alabdalhussein A, et al
    Incidence of retropharyngeal lymph node involvement in oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis.
    Oral Oncol. 2026;181:108090.
    PubMed     Abstract available
    
    
    
15. YANAN D, Zhao T, Chuanliang S, Junzheng W, et al
    Comments on: prognostic value of the 5-Item Modified Frailty Index in elderly patients undergoing free flap reconstruction for head and neck cancer.
    Oral Oncol. 2026;182:108154.
    PubMed    
    
    
    September 2026
16. LONG CQ
    Interpreting distant metastasis risk in MRI-Defined N3 nasopharyngeal carcinoma in the presence of competing events.
    Oral Oncol. 2026;182:108160.
    PubMed    
    
    
    
17. SMITH JD, Santiago R, Doerfler R, Harris MK, et al
    The impact of regional lymph node depletion on response to anti-PD-1 therapy in recurrent and metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2026;182:108155.
    PubMed     Abstract available
    
    
    
18. URAGUCHI K, Rikitake R, Tsumura M, Ando M, et al
    Board-certified facilities and survival in head and neck cancer in Japan: A hospital-based cancer registry study.
    Oral Oncol. 2026;182:108152.
    PubMed     Abstract available
    
    
    
19. PATEL AN, Wu SS, Colevas AD, Divi V, et al
    Estimated costs of intravenous vs subcutaneous pembrolizumab in perioperative head and neck cancer: subcutaneous administration is unlikely to reduce costs.
    Oral Oncol. 2026;182:108125.
    PubMed    
    
    
    
20. CHEN F, Yang X
    Letter to the Editor: Exercise prehabilitation in head and neck cancer patients proposed for definitive chemoradiotherapy: The FIT4TREAT randomized controlled trial.
    Oral Oncol. 2026;182:108144.
    PubMed    
    
    
    
21. HONGO T, Watanuki Y, Hirano Y, Yamauchi M, et al
    Prognostic impact of osteosarcopenia in patients with head and neck cancer undergoing radical resection and reconstructive surgery.
    Oral Oncol. 2026;182:108141.
    PubMed     Abstract available
    
    
    
22. WANG Y, You K, Lan X, Liang P, et al
    Pretreatment MRI-defined necrotic nodal phenotypes identify distant metastasis risk heterogeneity in N3 nasopharyngeal carcinoma.
    Oral Oncol. 2026;182:108135.
    PubMed     Abstract available
    
    
    
23. HONG MH, Lee S, Kim CG, Son W, et al
    Corrigendum to "A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma" [Oral Oncol. 170 (2025) 107745].
    Oral Oncol. 2026 Sep 4:108114. doi: 10.1016/j.oraloncology.2026.108114.
    PubMed    
    
    
    
24. OKUYAMA K, Yanamoto S
    Integrating minimal residual disease into postoperative treatment selection for head and neck cancer.
    Oral Oncol. 2026;182:108121.
    PubMed     Abstract available
    
    
    
25. KHADERI IM, Kandahari N, Saleh AW, Hackman TG, et al
    Development of the TORS severe outcome score: a preoperative risk stratification tool for postoperative morbidity in oropharyngeal cancer.
    Oral Oncol. 2026;180:108058.
    PubMed     Abstract available
    
    
    
26. THARIAT J, Marcy PY, Preudhomme R, Gadan C, et al
    Postoperative radiotherapy delineation after mandibular bone flap reconstruction in oral cavity and oropharyngeal cancers.
    Oral Oncol. 2026;180:108054.
    PubMed     Abstract available
    
    
    
27. ZADIK Y, Gavish L, Hanut A, Finfter O, et al
    High-power laser photobiomodulation therapy for immediate relief of mucositis-related odynophagia.
    Oral Oncol. 2026;180:108049.
    PubMed     Abstract available
    
    
    
28. STROJAN P, Zagar T, Sifrer R, Didanovic V, et al
    Primary treatment modalities and p16 status in oropharyngeal squamous cell carcinoma outcomes: a tertiary center study with propensity score analysis.
    Oral Oncol. 2026;180:108039.
    PubMed     Abstract available
    
    
    August 2026
29. GARCIA C, Leao I, Pinto D, Rato ND, et al
    Exercise prehabilitation in head and neck cancer patients proposed for definitive chemoradiotherapy: The FIT4TREAT randomized controlled trial.
    Oral Oncol. 2026;181:108119.
    PubMed     Abstract available
    
    
    
30. FILIPPINI DM, Carosi F, Tomaciello M, Monte A, et al
    HPV circulating tumor DNA as a potential prognostic and predictive biomarker in head and neck squamous cell carcinoma: a systematic review.
    Oral Oncol. 2026;181:108116.
    PubMed     Abstract available
    
    
    
31. BRADSHAW J, Tardif J, Lott DG, Ramaswamy AT, et al
    Radiation-associated dysphagia in head and neck cancer: A narrative review of surgical management, diagnosis, and emerging directions.
    Oral Oncol. 2026;181:108118.
    PubMed     Abstract available
    
    
    
32. CLATOT F, Vozy A, Dominiak G, Luciani L, et al
    Real-world treatment sequences and outcomes in recurrent/metastatic head and neck squamous cell carcinoma in France (TERENCE study).
    Oral Oncol. 2026;181:108106.
    PubMed     Abstract available
    
    
    
33. LI L, Wang Z, Qin Z, Cai Z, et al
    Association of glycaemic control with post-radiation nasopharyngeal necrosis in diabetic patients with nasopharyngeal carcinoma.
    Oral Oncol. 2026;181:108112.
    PubMed     Abstract available
    
    
    
34. THOMAS EA, Liu J, Yu M, Heft Neal ME, et al
    Rural-Urban disparities in head and neck cancer mortality in the United States: Subsite-Specific Trends, 2010-2024.
    Oral Oncol. 2026;181:108111.
    PubMed    
    
    
    
35. DALMEIJER SWR, Baidun AS, Sjogren EV, Dronkers EAC, et al
    Positive Margin Rate Following Transoral Surgery in T2-T3 Laryngeal Carcinoma - a Systematic Review and Meta-Analysis.
    Oral Oncol. 2026;181:108113.
    PubMed     Abstract available
    
    
    
36. SOBHANI S
    Promise and pitfalls of structure-based classification of radiologic extranodal extension in nasopharyngeal carcinoma.
    Oral Oncol. 2026;181:108109.
    PubMed    
    
    
    
37. MATSUDA Y, Fujioka-Kobayashi M, Tatsumi H, Sonoyama-Osako R, et al
    Exploratory estimation of minimal clinically important deterioration in oral and swallowing function after oral cancer treatment: A prospective observational study.
    Oral Oncol. 2026;181:108108.
    PubMed     Abstract available
    
    
    
38. DIETZE A, Zabini A, Schanne DH, Elicin O, et al
    De-escalation of radiotherapy in HPV-negative non-nasopharyngeal head and neck squamous cell carcinoma: a systematic review.
    Oral Oncol. 2026;181:108095.
    PubMed     Abstract available
    
    
    
39. WU H
    Caution is warranted before omitting neck dissection after neoadjuvant chemoimmunotherapy in cT3-4N0M0 oral squamous cell carcinoma.
    Oral Oncol. 2026;181:108105.
    PubMed    
    
    
    
40. LIU R, Wang Z, Yang X, He J, et al
    Health-Related quality of life (HRQoL) and health state utility values (HSUV) in patients with head and neck Cancer: A systematic review and Meta-Analysis.
    Oral Oncol. 2026;181:108097.
    PubMed     Abstract available
    
    
    
41. TOPKAN E, Selek U
    Comment on Impact of metastasis-directed therapy for metachronous thoracic metastases following definitive (chemo)radiotherapy in p16-positive head and neck squamous cell carcinoma.
    Oral Oncol. 2026;181:108096.
    PubMed    
    
    
    
42. SUDARSON J
    Commentary on "Risk-benefit stratification for immune checkpoint inhibitor therapy in head and neck cancer based on immune-related adverse events and treatment discontinuation using routine clinical indicators beyond PD-L1 expression".
    Oral Oncol. 2026;181:108099.
    PubMed     Abstract available
    
    
    
43. NAGAOKA M, Omura K, Fukuzato S, Ishida K, et al
    Early oncologic outcomes of endoscope-assisted total maxillectomy for maxillary sinus squamous cell carcinoma: A comparative study with conventional surgery.
    Oral Oncol. 2026;179:108023.
    PubMed     Abstract available
    
    
    
44. OHKOSHI A, Katagiri K, Kano S, Yagi K, et al
    Treatment and prognosis of subglottic cancers: a 10-year, multicenter, retrospective study in northern Japan.
    Oral Oncol. 2026;179:108021.
    PubMed     Abstract available
    
    
    
45. BROWN MH, Mendes WS, Song Y, Shetty AC, et al
    High frequency of RB1 mutations p16 positive early stage oropharyngeal carcinoma: A genomic and transcriptomic analysis.
    Oral Oncol. 2026;179:108002.
    PubMed     Abstract available
    
    
    July 2026
46. TALOR E, Lavin P, Cipriano J, Markovic D, et al
    A novel neoadjuvant immunotherapy confers improved overall survival in oral cancer patients with low tumor PD-L1 expression The IT-MATTERS Clinical trial - Prognostic role of tumor PD-L1 expression.
    Oral Oncol. 2026;181:108092.
    PubMed     Abstract available
    
    
    
47. SYKES J, Uribe Sanchez ED, Benito D, Danyluk A, et al
    Prognostic value of the 5-Item Modified Frailty Index in elderly patients undergoing free flap reconstruction for head and neck cancer.
    Oral Oncol. 2026;181:108088.
    PubMed     Abstract available
    
    
    
48. GIUDICI F, Polesel J, Tagliabue M, Fratta E, et al
    Evolution of hazard of recurrence and death after surgery for oropharyngeal cancer according to HPV status.
    Oral Oncol. 2026;181:108079.
    PubMed     Abstract available
    
    
    
49. TOPKAN E, Selek U
    Comment on "Elective neck dissection and adjuvant therapy in N0 major salivary gland cancer: an analysis of the SEER cancer database".
    Oral Oncol. 2026;181:108091.
    PubMed    
    
    
    
50. GARCIA-AGULLO J, Santos V, Garcia-Mayea Y, de Luxan-Delgado B, et al
    NGFR expression predicts tumor recurrence in radiotherapy/chemoradiotherapy-treated HPV-negative pharyngeal squamous cell carcinoma.
    Oral Oncol. 2026;180:108080.
    PubMed     Abstract available
    
    
    
51. SHARMAN MOSER S, Ziv D, Hoshen M, Gazit S, et al
    REVEAL study - real-world database analysis of patients with locally advanced head and neck squamous cell carcinoma in Israel.
    Oral Oncol. 2026;180:108077.
    PubMed     Abstract available
    
    
    
52. ZHU B, Wen Z, Chen K, Zhu L, et al
    Pretreatment multiparametric MRI-based habitat radiomics and 2.5D deep learning for predicting early complete response to induction chemoimmunotherapy in locally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2026;180:108072.
    PubMed     Abstract available
    
    
    
53. FANG Q, Cao F, Zhao Z, Lin R, et al
    omitting neck dissection in cT3-4N0M0 oral squamous cell carcinoma with Imaging-Negative nodes after neoadjuvant chemoimmunotherapy: A retrospective cohort study.
    Oral Oncol. 2026;180:108076.
    PubMed     Abstract available
    
    
    
54. YAMIN T, Bergman D, Bartal K, Tiomkin E, et al
    The gender gap in HPV Literacy: A Cross-Sectional study of patient awareness of HPV-Related oropharyngeal carcinoma in men in the vaccine era.
    Oral Oncol. 2026;180:108075.
    PubMed     Abstract available
    
    
    
55. HAM ND, Ershadifar S, Garber B, Li M, et al
    Patient preferences for mental health care in head and neck cancer: A head and neck cancer Alliance survey.
    Oral Oncol. 2026;180:108074.
    PubMed     Abstract available
    
    
    
56. GAFFNEY J, France A, Rieu R, Wang Y, et al
    Evaluation of radiotherapy dose and survival outcomes for teenagers, and young adults with nasopharyngeal carcinoma in UK & Ireland.
    Oral Oncol. 2026;180:108062.
    PubMed     Abstract available
    
    
    
57. KABONGO CM, Bowman T, Tracy J, Soneru C, et al
    Changing epidemiology of sinonasal cancer in the United States.
    Oral Oncol. 2026;178:107996.
    PubMed     Abstract available
    
    
    June 2026
58. TOPKAN E, Somay E, Selek U
    Re: Ensemble learning-based radiomics model for predicting radiation-induced temporal lobe injury in nasopharyngeal carcinoma.
    Oral Oncol. 2026;180:108067.
    PubMed    
    
    
    
59. OU C, Qi L, Lai H, Ye J, et al
    Mechanisms and clinical challenges of ICB-mediated remodeling of the tumor microenvironment in nasopharyngeal carcinoma.
    Oral Oncol. 2026;180:108017.
    PubMed     Abstract available
    
    
    
60. LYU Y, Chen L, Cen X, Deng Y, et al
    The survival benefit of postoperative radiotherapy in pN1 head and neck squamous cell carcinoma without adverse pathological features: analysis of the SEER database.
    Oral Oncol. 2026;180:108055.
    PubMed     Abstract available
    
    
    
61. HONG MH, Lee S, Kim CG, Son W, et al
    Corrigendum to "A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma" [Oral Oncol. 170 (2025) 107745].
    Oral Oncol. 2026 Jun 20:108052. doi: 10.1016/j.oraloncology.2026.108052.
    PubMed    
    
    
    
62. TOPKAN E, Selek U
    Evaluation of a quasi-automatic treatment planning workflow for head-and-neck cancer in radiotherapy.
    Oral Oncol. 2026;180:108059.
    PubMed    
    
    
    
63. TAPESCU I, Brody RM, Cao AC, Le K, et al
    Predictors and outcomes of pathologic retropharyngeal lymph nodes in HPV-related oropharyngeal cancer.
    Oral Oncol. 2026;180:108056.
    PubMed     Abstract available
    
    
    
64. LIU J, Fan Y, He C, Jin T, et al
    Structure-specific involvement in advanced cervical lymph node extranodal extension predicts prognosis in nasopharyngeal carcinoma: A multi-center study.
    Oral Oncol. 2026;180:108050.
    PubMed     Abstract available
    
    
    
65. XUE L, Zhou J, Tang W, Zhao W, et al
    Intravenous amivantamab after cetuximab failure in recurrent or metastatic head and neck squamous cell carcinoma: a single-centre retrospective real-world cohort study.
    Oral Oncol. 2026;180:108051.
    PubMed     Abstract available
    
    
    
66. BOLDES T, Oanunu U, Machnes O, Dudkiewicz D, et al
    Efficacy of cetuximab-based regimens after immune checkpoint inhibitor failure in recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and meta-analysis.
    Oral Oncol. 2026;180:108041.
    PubMed     Abstract available
    
    
    
67. JIA B, He M, Ren J, Li G, et al
    Development and internal validation of an explainable machine learning model for predicting textbook outcome after free flap reconstruction in oral cancer.
    Oral Oncol. 2026;179:108037.
    PubMed     Abstract available
    
    
    
68. NIJJAR YS, Sapir E, Corn BW, Gensheimer MF, et al
    Evaluation of the ESMO-magnitude of clinical benefit scale version 2.0 for the definitive treatment of HPV positive oropharynx cancer with radiation therapy.
    Oral Oncol. 2026;179:108035.
    PubMed     Abstract available
    
    
    May 2026
69. WILLIAMSON A, Burton S, Rajan Z, Kwong E, et al
    Salvage surgery for residual and recurrent head and neck squamous cell carcinoma (RESCUE): An IReC multicentre consecutive cohort study.
    Oral Oncol. 2026;179:107997.
    PubMed     Abstract available
    
    
    
70. STAIBANO P, Au M, Ganly I, de Almeida JR, et al
    Elective neck dissection and adjuvant therapy in N0 major salivary gland cancer: An analysis of the SEER cancer database.
    Oral Oncol. 2026;179:108015.
    PubMed     Abstract available
    
    
    
71. COSTANTINO A, Paleri V, Williamson A, Zhu J, et al
    Optimizing adjuvant therapy selection with machine learning after transoral surgery in HPV-related oropharyngeal cancer.
    Oral Oncol. 2026;179:108024.
    PubMed     Abstract available
    
    
    
72. SCHAFER A, Zulch L, Steinsdorfer L, Donaubauer AJ, et al
    ATR inhibition in combination with hypofractionated radiotherapy is superior to ATM inhibition with regard to ex vivo CD8 + T cell activation particularly for HPV-negative head and neck cancer cells.
    Oral Oncol. 2026;179:108019.
    PubMed     Abstract available
    
    
    
73. NEMADE H, Thaduri A, Gondi JT, Chava SK, et al
    Refining nodal classification in oral cancer: prognostic impact of nodal burden within N2b and implications for AJCC staging.
    Oral Oncol. 2026;179:108016.
    PubMed     Abstract available
    
    
    
74. WANG L, Hu H
    Analytical validity and interpretive boundaries of circulating immunosenescence-related indicators in head and neck squamous cell carcinoma.
    Oral Oncol. 2026;179:108008.
    PubMed    
    
    
    
75. ZHOU Y, Chen C
    A thoughtful reflection on survival outcomes after sentinel lymph node biopsy versus elective neck dissection in early oral cancer.
    Oral Oncol. 2026;179:108011.
    PubMed    
    
    
    
76. BAGCHI P, Baviskar P, Yennemadi S
    Considerations regarding functional suprahyoid neck dissection in early lower lip carcinoma.
    Oral Oncol. 2026;179:108013.
    PubMed    
    
    
    
77. GAUDUCHON T, Digue L, Ferlay C, Treilleux I, et al
    Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial.
    Oral Oncol. 2026;178:108004.
    PubMed     Abstract available
    
    
    
78. LY S, Ruhle A, Bratman S, Cho J, et al
    Impact of metastasis-directed therapy for metachronous thoracic metastases following definitive (chemo)radiotherapy in p16-positive head and neck squamous cell carcinoma.
    Oral Oncol. 2026;178:108006.
    PubMed     Abstract available
    
    
    
79. ROOF SA, Sicard RM, Chennareddy S, Ahn S, et al
    Post-treatment circulating tumor DNA clinical features, prognosis in HPV-positive oropharynx cancer.
    Oral Oncol. 2026;178:108003.
    PubMed     Abstract available
    
    
    
80. YILDIZ I, Tasci ES, Yucel S
    HPV-positive oropharyngeal squamous cell carcinoma: risk-adapted treatment strategies and biomarker-guided individualization.
    Oral Oncol. 2026;178:108005.
    PubMed     Abstract available
    
    
    
81. GRIFFIN C, Donovan ML, Lawler C, Da Gama Duarte J, et al
    Tertiary lymphoid structures in head and neck squamous cell carcinoma as predictors of response to immunotherapy.
    Oral Oncol. 2026;178:107998.
    PubMed     Abstract available
    
    
    
82. ZHANG Y, Lv P, Cao G, Qi N, et al
    A kinase-related gene signature predicts prognosis and therapeutic response in head and neck squamous cell carcinoma.
    Oral Oncol. 2026;178:107981.
    PubMed     Abstract available
    
    
    
83. ADIL AA, Smith JD, Almasri M, Lyden T, et al
    In-office secondary tracheoesophageal puncture with immediate voicing in post-laryngectomy patients.
    Oral Oncol. 2026;176:107951.
    PubMed     Abstract available
    
    
    
84. LITTLE S, Williams MF, Gilkey M, Perez-Bello D, et al
    Veteran oropharyngeal cancer outcomes in the modern era: a multi-institutional retrospective analysis.
    Oral Oncol. 2026;176:107942.
    PubMed     Abstract available
    
    
    
85. KIUCHI S, Matsuyama Y, Takeuchi K, Kusama T, et al
    Smoking, drinking, tooth loss and risk of oral-pharyngeal cancer mortality.
    Oral Oncol. 2026;176:107937.
    PubMed     Abstract available
    
    
    
86. CHU F, Bandi F, Tagliabue M, Zorzi SF, et al
    Transoral laser microsurgery for glottic cancer: landmark 24-year single-institution experience with 661 patients and validation of the isoprognostic zone system.
    Oral Oncol. 2026;176:107917.
    PubMed     Abstract available
    
    
    
87. WANG YT, Chu PY
    A single transoral laser microsurgery to simultaneously diagnose and treat early glottic cancer and premalignancies.
    Oral Oncol. 2026;176:107920.
    PubMed     Abstract available
    
    
    
88. NAGENDRABALAN N, Sahovaler A, Payne K, Shamat HA, et al
    Survival in node-positive early oral squamous cell carcinoma following sentinel lymph node biopsy or elective neck dissection.
    Oral Oncol. 2026;178:107971.
    PubMed     Abstract available
    
    
    April 2026
89. ZHAO Z, Guo Y
    Comment on "Sex-based immune differences influence tumor progression in head and neck squamous cell carcinoma".
    Oral Oncol. 2026;178:107995.
    PubMed    
    
    
    
90. BAKHTIAR M, Al-Inaya Y, Das D, Margalit DN, et al
    Clearance of circulating HPV DNA during chemoradiation using a next-generation sequencing liquid biopsy.
    Oral Oncol. 2026;178:107984.
    PubMed     Abstract available
    
    
    
91. ABOU-FOUL AK, Kristunas C, Henson C, Andrew D, et al
    Correlation between head and neck radiologists reporting on extranodal extension detected on radiological imaging: A head and neck cancer international group multinational study.
    Oral Oncol. 2026;178:107980.
    PubMed     Abstract available
    
    
    
92. GULMEZ E, Ozdemir AC, Al EA, Kara I, et al
    Evaluation of long-term outcomes of functional suprahyoid neck dissection in patients with early-stage lower lip cancer.
    Oral Oncol. 2026;177:107978.
    PubMed     Abstract available
    
    
    
93. YOKOTA T, Kiyota N, Kodaira T, Nishino H, et al
    Risk factors for aspiration pneumonia related to postoperative chemoradiotherapy for high-risk head and neck cancer: A supplementary analysis of a phase II/III JCOG1008 trial.
    Oral Oncol. 2026;177:107977.
    PubMed     Abstract available
    
    
    
94. CHEN W, Ye K
    Comment on "Prognostic significance of p16 and immune cell infiltration in recurrent/metastatic head and neck squamous cell carcinoma treated with PD-1 inhibition: a national DAHANCA cohort study".
    Oral Oncol. 2026;177:107972.
    PubMed    
    
    
    
95. HUANG CC, Hsiao JR, Wang WM, Wang F, et al
    Early diagnosis and treatment of oral cancer in workers was associated with reduced losses of healthy life expectancy and productivity: real-world evidence from Taiwan during 2010-2019.
    Oral Oncol. 2026;177:107969.
    PubMed     Abstract available
    
    
    
96. RUSSI EG
    Randomizing treatment is not equivalent to validating biomarker-guided intensification in high-risk nasopharyngeal carcinoma.
    Oral Oncol. 2026;177:107970.
    PubMed    
    
    
    
97. COSSU ROCCA M, Esposito A, Vecchio S, Nicolai P, et al
    A prospective study with Comprehensive Geriatric Assessment (CGA) before curative treatment in older patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
    Oral Oncol. 2026;177:107968.
    PubMed     Abstract available
    
    
    
98. CHAKRABARTY N, Dadlani T, Mahajan A, Laskar SG, et al
    Diagnostic value of MRI-based iENE assessment for predicting major and minor extranodal extension in oral tongue carcinoma.
    Oral Oncol. 2026;177:107960.
    PubMed     Abstract available
    
    
    
99. ALABEEDI F, Zheng M, Kataria A, Malki MI, et al
    Clinical efficacy of chemopreventive agents in oral cancer and oral potentially malignant disorders: A systematic review.
    Oral Oncol. 2026;177:107961.
    PubMed     Abstract available
    
    
    
100. BOONE G, Davis KP, Zhang Z, Elledge CR, et al
     Defining platinum-ineligible head and neck cancer patients from administrative data.
     Oral Oncol. 2026;177:107953.
     PubMed     Abstract available
     
     
     
101. HUANG YJ, Fang KC, Tsai MH, Chuang HC, et al
     Swallowing-related outcomes and organ-at-risk dosimetry after proton versus photon radiotherapy in nasopharyngeal carcinoma.
     Oral Oncol. 2026;175:107906.
     PubMed     Abstract available
     
     
     
102. CRACCHIOLO JR, Kavanagh F, Starc MT, Scholfield D, et al
     Defining response-adapted surgery after neoadjuvant systemic therapy in sinonasal squamous cell carcinoma.
     Oral Oncol. 2026;175:107882.
     PubMed     Abstract available
     
     
     
103. PARK H, Kim BR, Yoo JH, Kim SW, et al
     Clinical implication of the 2025 ATA risk stratification in follicular thyroid carcinoma: A comparison with the 2015 ATA risk stratification.
     Oral Oncol. 2026;175:107912.
     PubMed     Abstract available
     
     
     
104. MANFUSO A, Cirignaco G, Cocis S, Volpe F, et al
     Selective tracheostomy in oral cancer reconstruction with myomucosal flaps: Outcomes and an appraisal of published risk scores.
     Oral Oncol. 2026;175:107916.
     PubMed     Abstract available
     
     
     
105. NGO DQ, Le DT, Ngo QX, Le QV, et al
     Surgical outcomes of modified versus conventional transoral endoscopic thyroidectomy vestibular approach for papillary thyroid carcinoma.
     Oral Oncol. 2026;175:107908.
     PubMed     Abstract available
     
     
     March 2026
106. YAMADA T, Okuyama K, Hamada A, Yanamoto S, et al
     Interpreting neoadjuvant chemo-immunotherapy through tumor microenvironment dynamics in head and neck cancer.
     Oral Oncol. 2026;176:107958.
     PubMed    
     
     
     
107. MASCARELLA MA, Mlynarek A, Richardson K, Vendra V, et al
     Predicting treatment intolerance in operable head and neck cancer using the modified head and neck surgery risk index.
     Oral Oncol. 2026;176:107943.
     PubMed     Abstract available
     
     
     
108. LI J
     Sex-specific immune determinants in head and neck squamous cell carcinoma: bridging preclinical insights to clinical translation.
     Oral Oncol. 2026;176:107950.
     PubMed    
     
     
     
109. HAN J
     Comment on "Selective tracheostomy in oral cancer reconstruction with myomucosal flaps: Outcomes and an appraisal of published risk scores".
     Oral Oncol. 2026;176:107955.
     PubMed    
     
     
     
110. DU C, Zhai R, Kong F, Niu X, et al
     Prognostic value of early Epstein-Barr Virus DNA response in patients with locoregionally advanced nasopharyngeal carcinoma.
     Oral Oncol. 2026;176:107934.
     PubMed     Abstract available
     
     
     
111. TOPKAN E, Selek U
     Comment on low-dose fractionated radiotherapy during induction chemotherapy for node-positive locoregionally advanced nasopharyngeal carcinoma: a randomized phase II trial.
     Oral Oncol. 2026;176:107940.
     PubMed    
     
     
     
112. KASAHARA K, Kono T, Sato Y, Okubo K, et al
     Risk-benefit stratification for immune checkpoint inhibitor therapy in head and neck cancer based on immune-related adverse events and treatment discontinuation using routine clinical indicators beyond PD-L1 expression.
     Oral Oncol. 2026;176:107938.
     PubMed     Abstract available
     
     
     
113. KOCH N, Yosefof E, Gleber-Netto FO, Amir I, et al
     Elective neck irradiation does not improve regional control or survival in pT3-T4N0 oral cavity SCC after high-yield neck dissection: A retrospective multicenter analysis.
     Oral Oncol. 2026;176:107946.
     PubMed     Abstract available
     
     
     
114. LEE SF, Hircock C, Yip PL, Cheo T, et al
     Limitations of quality-of-life assessment and long-term side effects in nasopharyngeal carcinoma: a narrative review.
     Oral Oncol. 2026;176:107935.
     PubMed     Abstract available
     
     
     
115. JAGADEESHA S, Lamenza F, Upadhaya P, Chung C, et al
     Sex-based immune differences influence tumor progression in head and neck squamous cell carcinoma.
     Oral Oncol. 2026;176:107929.
     PubMed     Abstract available
     
     
     
116. DOU K, Liu D, Shi Y, Qin H, et al
     Can the submandibular gland be preserved during neck dissection in patients with oral squamous cell carcinoma?A systematic review and meta-analysis.
     Oral Oncol. 2026;176:107913.
     PubMed     Abstract available
     
     
     
117. CARVALHO WA, Carvalho AA, Silveira AA
     Transoral robotic surgery versus definitive (Chemo)radiotherapy in early HPV-positive oropharyngeal cancer: A systematic review and meta-analysis of oncologic outcomes.
     Oral Oncol. 2026;176:107930.
     PubMed     Abstract available
     
     
     
118. DAI WF, Nguyen L, Liu N, Chan KK, et al
     Corrigendum to "Real-world effectiveness and healthcare utilization of nivolumab for advanced head and neck cancer: A real-world population-based descriptive study" [Oral Oncol. 173 (2026) 107851].
     Oral Oncol. 2026 Mar 5:107919. doi: 10.1016/j.oraloncology.2026.107919.
     PubMed    
     
     
     
119. SHIMIZU T, Takahashi H, Tada H, Chikamatsu K, et al
     Integrative analysis of aging-related immune parameters reveals prognostic and immunotherapeutic implications in head and neck squamous cell carcinoma.
     Oral Oncol. 2026;176:107914.
     PubMed     Abstract available
     
     
     
120. CHU F, Benzi P, Tagliabue M, Mossinelli C, et al
     Rare laryngeal tumors: A retrospective bicentric study on 74 patients and systematic review.
     Oral Oncol. 2026;174:107852.
     PubMed     Abstract available
     
     
     
121. WOJTERA BP, Beharry A, Salati V, Lambercy K, et al
     Long-term swallowing outcomes following transoral robotic surgery for oropharyngeal cancer - Five years and beyond.
     Oral Oncol. 2026;174:107876.
     PubMed     Abstract available
     
     
     February 2026
122. ZHAO ZY, He SQ, Liu GY, Lv SH, et al
     Efficacy of radiotherapy to metastatic lesion in de novo metastatic nasopharyngeal carcinoma patients: A multicenter, propensity score matching study.
     Oral Oncol. 2026;175:107907.
     PubMed     Abstract available
     
     
     
123. NTOUKAS SM, Mohamad N, Boparai R, Dennett L, et al
     Effects of exercise on health-related fitness and patient-reported outcomes in survivors of head and neck cancer: a systematic review and meta-analysis.
     Oral Oncol. 2026;175:107902.
     PubMed     Abstract available
     
     
     
124. BHATI M, Bagchi P, Pawar P, Baviskar P, et al
     Aberrant lateral position of external carotid artery, a surgical pitfall during neck dissection.
     Oral Oncol. 2026;175:107905.
     PubMed    
     
     
     
125. HOLGADO A, Llansana A, Vazquez C, Gallego O, et al
     Identification of prognostic variables in patients with recurrent head and neck squamous cell carcinoma treated with salvage surgery: Implications for treatment with immunotherapy.
     Oral Oncol. 2026;175:107903.
     PubMed     Abstract available
     
     
     
126. ECONOMOPOULOU P, Pouliakis A, Kyprianou M, Pantazopoulos A, et al
     An observational retro-prospective study on patients with head and neck cancer who contracted COVID-19 (HERODOTUS: head and neck cancERs international cOviD-19 collabOraTion).
     Oral Oncol. 2026;175:107900.
     PubMed     Abstract available
     
     
     
127. MARGONI A, Papavassiliou KA, Papavassiliou AG
     From heterogeneity to molecular stratification: A multiplex genomic panel for tailored therapy of head and neck squamous cell carcinoma.
     Oral Oncol. 2026;175:107904.
     PubMed     Abstract available
     
     
     
128. LI C, Xiao X, Jiang H, Li B, et al
     Comparable survival after lobectomy and total thyroidectomy for T3b differentiated thyroid carcinoma: A population-based study.
     Oral Oncol. 2026;175:107891.
     PubMed     Abstract available
     
     
     
129. XIN Y, Yang L, Liu C, Li D, et al
     Spatial transcriptomics of immune ecotypes for predicting immunotherapy outcomes in head and neck squamous cell carcinoma.
     Oral Oncol. 2026;175:107887.
     PubMed     Abstract available
     
     
     
130. FAN M, Yin Q, Li L, Lian Q, et al
     Low-dose fractionated radiotherapy combined with induction chemotherapy in high-risk nasopharyngeal carcinoma: An open-label, randomized phase 2 trial.
     Oral Oncol. 2026;175:107888.
     PubMed     Abstract available
     
     
     
131. BENITES C, White C, Balaguru L, Gonghao L, et al
     Does discharge location following head and neck cancer surgery affect quality outcomes?
     Oral Oncol. 2026;175:107879.
     PubMed     Abstract available
     
     
     
132. SINGH SP, Prasad S, Dean PM, Kujur AL, et al
     Prognostic significance of extranodal extension in cervical lymph node metastases of head and neck squamous cell carcinoma: A systematic review and meta-analysis with bibliometric overview.
     Oral Oncol. 2026;174:107862.
     PubMed     Abstract available
     
     
     
133. ZHANG L
     Comment on "Risk factors and a risk assessment model for venous thromboembolism in head and neck cancer surgery".
     Oral Oncol. 2026;174:107881.
     PubMed    
     
     
     
134. ROY P, Weber MB, Gupta R, Kakkar A, et al
     The prognostic significance of the 'Worst Pattern of Invasion' in oral cancers-an international collaborative multicentre analysis.
     Oral Oncol. 2026;174:107874.
     PubMed     Abstract available
     
     
     
135. TAKAHASHI Y, Bell D, Corona A, Su SY, et al
     Establishment of novel stable human sinonasal NUT carcinoma cell lines.
     Oral Oncol. 2026;173:107828.
     PubMed     Abstract available
     
     
     January 2026
136. HACK S, Karni RJ, Maniaci A, Fundakowski CE, et al
     Evaluation of large language models as decision support tools for head and neck cancer management: A blinded multidisciplinary simulation study.
     Oral Oncol. 2026;174:107877.
     PubMed     Abstract available
     
     
     
137. WANG N, Gao H, Yu SX, Fan J, et al
     The first report of contralateral parapharyngeal space metastasis of papillary thyroid carcinoma: report of a case.
     Oral Oncol. 2026;174:107865.
     PubMed    
     
     
     
138. ZHONG J, Chen H, Yan Z, Xu H, et al
     Refinement of N category in version-nine of AJCC/UICC TNM staging system for nasopharyngeal carcinoma based on the international consensus recommendations for diagnosing extranodal extension.
     Oral Oncol. 2026;174:107866.
     PubMed     Abstract available
     
     
     
139. ALMEIDA ND, Schrand TV, Sullivan D, Yu H, et al
     Prognostic associations of systemic inflammation response index (SIRI) in patients with head and neck cancer: a systematic review and meta-analysis.
     Oral Oncol. 2026;174:107859.
     PubMed     Abstract available
     
     
     
140. LOVETT JT, Wotman MT, Westra WH, Ahn S, et al
     Long-Term outcomes of induction chemotherapy-guided reduced-dose chemoradiotherapy in poor-risk HPV-Positive oropharyngeal Cancer: Results from the sequential quarterback trials.
     Oral Oncol. 2026;174:107858.
     PubMed     Abstract available
     
     
     
141. CHENG C, Zhang J
     Advancing methodological rigor in exercise oncology trials for head and neck cancer.
     Oral Oncol. 2026;173:107857.
     PubMed    
     
     
     
142. CAROSI F, Demurtas S, Ciarfella A, Orlandi E, et al
     Perioperative immunotherapy for head and neck cancer: from early successes to clinical challenges in relapsed and/or metastatic disease.
     Oral Oncol. 2026;173:107853.
     PubMed    
     
     
     
143. WANG W, Lou Y
     From risk factors to clinical Decisions: Methodological Considerations in Predicting occult metastasis in papillary thyroid carcinoma.
     Oral Oncol. 2026;173:107854.
     PubMed    
     
     
     
144. SOBY S, Mortensen D, Gothelf A, Gyldenkerne N, et al
     Prognostic significance of p16 and immune cell infiltration in recurrent/metastatic head and neck squamous cell carcinoma treated with PD-1 inhibition: a national DAHANCA cohort study.
     Oral Oncol. 2026;173:107849.
     PubMed     Abstract available
     
     
     
145. DAI WF, Nguyen L, Liu N, Chan KK, et al
     Real-world effectiveness and healthcare utilization of nivolumab for advanced head and neck cancer: A real-world population-based descriptive study.
     Oral Oncol. 2026;173:107851.
     PubMed     Abstract available
     
     
     
146. MARGONI A, Papavassiliou KA, Papavassiliou AG
     Harnessing TP53 mutational status to enhance prognostic precision and therapeutic effectiveness in head and neck squamous cell carcinoma.
     Oral Oncol. 2026;173:107846.
     PubMed    
     
     
     
147. WU WJ, An PG, Zhang ZQ, Shen LH, et al
     Neoadjuvant tislelizumab plus chemotherapy in locally advanced oral and oropharyngeal squamous cell carcinoma: A single-arm phase II clinical trial.
     Oral Oncol. 2026;172:107809.
     PubMed     Abstract available
     
     
     
148. NIU S, Ding J, Chen H, Zhu Z, et al
     Positron emission tomography-based intratumoral spatial diversity for prognosis in nasopharyngeal carcinoma.
     Oral Oncol. 2026;173:107845.
     PubMed     Abstract available
     
     
     December 2025
149. XIAO G, Ning L, Chen L, Zhang S, et al
     Exercise and quality of life in head and neck squamous cell carcinoma patients receiving neoadjuvant immuno-chemotherapy: A randomized, open-labeled phase II trial.
     Oral Oncol. 2025;173:107844.
     PubMed     Abstract available
     
     
     
150. JAKOBSEN KK, H Rasmussen J, Melchiors J, Agander TK, et al
     Head and neck cancer trends in Denmark: A nationwide, 40-Year data analysis.
     Oral Oncol. 2025;173:107843.
     PubMed     Abstract available
     
     
     
151. LECHIEN JR, Paleri V, Baudouin R, Brunet A, et al
     European surgical guidelines: transoral robotic surgery for head and neck cancers.
     Oral Oncol. 2025;173:107826.
     PubMed     Abstract available
     
     
     
152. CHAUDHRY M, Elfar A, Rowsey K, Neel A, et al
     Safety reporting in head and neck squamous cell carcinoma clinical Trials: A comparative analysis of ClinicalTrials.gov data and published research.
     Oral Oncol. 2025;173:107840.
     PubMed     Abstract available
     
     
     
153. ZHANG M, Song J, Yuan Y, Cao X, et al
     Ensemble learning-based radiomics model for predicting radiation-induced temporal lobe injury in nasopharyngeal carcinoma.
     Oral Oncol. 2025;173:107841.
     PubMed     Abstract available
     
     
     
154. PARK SE, Hong SH, Park JO, Kim SY, et al
     Head and neck squamous cell carcinoma following allogeneic bone marrow transplantation: Clinical features, genomic Alterations, and limited efficacy of palliative chemotherapy.
     Oral Oncol. 2025;173:107827.
     PubMed     Abstract available
     
     
     
155. THIAGARAJAN S, Rukmangathan T, Sharma D, Kakade A, et al
     Prevalence, risk Factors, and quality of life in patients with head and neck lymphedema following treatment for head and neck Cancer: The HeNLy-1 study.
     Oral Oncol. 2025;173:107838.
     PubMed     Abstract available
     
     
     
156. LIU Q, Wei JN, Zhou JY, Zhang CR, et al
     Development of a simplified scoring system for MRI-detected retropharyngeal lymph node features to optimize AJCC 9th edition N classification in nasopharyngeal carcinoma.
     Oral Oncol. 2025;173:107825.
     PubMed     Abstract available
     
     
     
157. ZOU C
     Letter to the editor: Stroke risk after head and neck cancer diagnosis and treatment in a Real-World clinical cohort.
     Oral Oncol. 2025;172:107705.
     PubMed    
     
     
     
158. CHOW VL, Ho VW, Lo AS
     Trans-hairline robotic neck dissection and robotic microvascular free flap reconstruction in oral cavity cancer.
     Oral Oncol. 2025;172:107819.
     PubMed     Abstract available
     
     
     
159. YOON HN, Kim JH, Gu D, Lee J, et al
     Patient-derived 3D organoid platform for functional assessment of GPC3-targeted CAR T cell cytotoxic activity in head and neck squamous cell carcinoma.
     Oral Oncol. 2025;172:107814.
     PubMed     Abstract available
     
     
     
160. SHAIKH MH, Gazala W, Zeng C, Naimi MF, et al
     NOTCH1 loss promotes chemo and radio-resistance in head and neck cancer.
     Oral Oncol. 2025;172:107815.
     PubMed     Abstract available
     
     
     
161. HACK S, Attal R, Geva K, Farzad A, et al
     Blinded comparative evaluation of GPT-generated, online search-derived, and guideline-based answers for HPV-associated oropharyngeal cancer.
     Oral Oncol. 2025;172:107813.
     PubMed     Abstract available
     
     
     
162. BARAN E, Lee M, Kamalraj P, Karam I, et al
     Cancer stage documentation and accuracy: Single-center retrospective study on oropharyngeal cancers.
     Oral Oncol. 2025;171:107795.
     PubMed     Abstract available
     
     
     
163. CHELVARAJAH RC, Huang SH, Su J, Gete M, et al
     Outcomes and characteristics of patients receiving pre-operative versus post-operative radiotherapy for sinonasal squamous cell carcinoma.
     Oral Oncol. 2025;171:107794.
     PubMed     Abstract available
     
     
     
164. CHONG CY, Young RJ, Lim AM, Pizzolla A, et al
     Evaluating CD103(+) intratumoral immune cell abundance and PD-L1 CPS in primary tumors versus lymph nodes in Human papillomavirus associated oropharyngeal Cancer.
     Oral Oncol. 2025;171:107792.
     PubMed     Abstract available
     
     
     
165. HIDALGO CM, Hernandez-Herrera GA, Day CN, Olawuni F, et al
     Access to surgery and high-quality radiotherapy for human papillomavirus related oropharynx cancer.
     Oral Oncol. 2025;171:107768.
     PubMed     Abstract available
     
     
     November 2025
166. LECHIEN JR
     Learning process of transoral robotic surgery for head and neck cancers: a scoping review.
     Oral Oncol. 2025;171:107788.
     PubMed     Abstract available
     
     
     
167. LI M, Zhou Y, Cai M
     Letter to the Editor: A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma.
     Oral Oncol. 2025;171:107784.
     PubMed    
     
     
     
168. OKURA M, Yamakawa N, Otsuru M, Hasegawa T, et al
     T4a classification for oral cancer using mandibular canal invasion instead of bone marrow invasion in the TNM staging system.
     Oral Oncol. 2025;171:107771.
     PubMed     Abstract available
     
     
     
169. DOERFLER R, Chen J, Kim C, Smith JD, et al
     Integrating artificial intelligence-driven digital pathology and genomics to establish patient-derived organoids as new approach methodologies for drug response in head and neck cancer.
     Oral Oncol. 2025;171:107742.
     PubMed     Abstract available
     
     
     
170. DIEZ-FRAILE A, Pottel L, Lamoral P, De Backer T, et al
     Age and surgical complexity outperform preoperative Geriatric-8 for 30-day major complications in older head and neck cancer.
     Oral Oncol. 2025;171:107774.
     PubMed    
     
     
     
171. VAN LOOCKE P, Beuselinck B, Meulemans J, Nuyts S, et al
     Impact of time-of-day administration of immune checkpoint inhibitors on survival outcomes in patients with recurrent/metastatic head and neck cancer (R/M HNSCC): a retrospective cohort study.
     Oral Oncol. 2025;171:107772.
     PubMed    
     
     
     
172. TIRELLI G, Boscolo-Rizzo P
     Perioperative pembrolizumab and the changing paradigm of adjuvant therapy in head and neck squamous cell carcinoma: the case of T1-2, pN1.
     Oral Oncol. 2025;171:107770.
     PubMed    
     
     
     
173. MASO V, Lechien JR, Gengler I, Chiesa-Estomba C, et al
     Management of head and neck cancer around the world: an international survey by the world ear, nose, and throat federation.
     Oral Oncol. 2025;171:107766.
     PubMed     Abstract available
     
     
     
174. WILLIAMS MM, Hanna GJ, Sethi RK, Rettig EM, et al
     Outcomes of oropharyngeal squamous cell carcinoma among patients with lymphoproliferative disorders.
     Oral Oncol. 2025;170:107761.
     PubMed     Abstract available
     
     
     
175. LI R, Ma S, Tang T, Zhao Y, et al
     Prognostic impact and risk factors of level IV/V lymph nodes metastasis in laryngeal squamous cell carcinoma.
     Oral Oncol. 2025;170:107758.
     PubMed     Abstract available
     
     
     
176. ZHU AQ, Cassianni CE, Haller T, O'Byrne TJ, et al
     Sensitivity of post-treatment surveillance in detecting recurrence and metastasis in surgically treated HPV-positive oropharyngeal squamous cell carcinoma patients.
     Oral Oncol. 2025;171:107767.
     PubMed     Abstract available
     
     
     October 2025
177. BERTIN B, Kowalski LP, Matos LL
     The low evidence to treat elderly patients with head and neck cancer.
     Oral Oncol. 2025;171:107764.
     PubMed     Abstract available
     
     
     
178. XIANG N, Li W
     Re: "Patterns of care in de?novo oligo?metastatic and oligo?recurrent head and neck cancers: A HNCIG survey" (Oral oncology).
     Oral Oncol. 2025;171:107749.
     PubMed    
     
     
     
179. DAS R, Misra SR, Mohapatra SSG
     Refining prognosis and Personalizing Therapy: A Step Forward with Machine learning in HPV-Associated head and neck cancer.
     Oral Oncol. 2025;170:107752.
     PubMed    
     
     
     
180. LIANG H, Guo Y
     Comment on "Massive nasal bleeding in nasopharyngeal carcinoma": Risk stratification and clinical implications.
     Oral Oncol. 2025;170:107755.
     PubMed    
     
     
     
181. HELOU V, Abdul-Rahman NH, Loo SK, Gao SJ, et al
     Circulating tumor DNA in Non-Viral head and neck squamous cell Carcinoma: A systematic review and Meta-Analysis.
     Oral Oncol. 2025;170:107760.
     PubMed     Abstract available
     
     
     
182. WANG Q, Yang Q, Wang Z, Duan X, et al
     Efficacy of primary lesion re-irradiation in nasopharyngeal carcinoma with synchronous recurrence and distant metastasis.
     Oral Oncol. 2025;170:107743.
     PubMed     Abstract available
     
     
     
183. KANG SK, Brooks E, Wolk R, Siriruchatanon M, et al
     Assessing liquid biopsy tests for the detection of head and neck squamous cell carcinoma: an umbrella review.
     Oral Oncol. 2025;170:107535.
     PubMed     Abstract available
     
     
     
184. BOIDE A, Glasmacher AR, Wurschi G, Tews AM, et al
     Fear of cancer recurrence in adults with p16-positive head and neck cancer after radiotherapy - Results from a multicenter cross-sectional observational study.
     Oral Oncol. 2025;170:107757.
     PubMed     Abstract available
     
     
     
185. HONG MH, Lee S, Kim CG, Son W, et al
     A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma.
     Oral Oncol. 2025;170:107745.
     PubMed     Abstract available
     
     
     
186. JEYARAJ G
     Commentary on "Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma".
     Oral Oncol. 2025 Oct 10:107741. doi: 10.1016/j.oraloncology.2025.107741.
     PubMed    
     
     
     
187. MARUDHUPANDI T
     Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma.
     Oral Oncol. 2025;170:107746.
     PubMed     Abstract available
     
     
     
188. LI Y, Tong S, Tian J, You X, et al
     Comment on: "Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: A pilot randomized controlled trial".
     Oral Oncol. 2025;170:107729.
     PubMed    
     
     
     
189. LI S, Garb BF, Qin T, Soppe SE, et al
     Tumor subtype classification tool for HPV-associated head and neck cancers.
     Oral Oncol. 2025;170:107726.
     PubMed     Abstract available
     
     
     
190. SWAIN M, Ghosh-Laskar S, McDowell L, Henson C, et al
     Patterns of care in de-novo oligo-metastatic and oligo-recurrent head and neck cancers: A Head and Neck Cancer International Group (HNCIG) Survey.
     Oral Oncol. 2025;170:107647.
     PubMed     Abstract available
     
     
     
191. VARETA JA, Zhang X, Kuhnell D, Hagen MC, et al
     Characterizing the mutational landscape of sinonasal squamous cell carcinoma using whole-exome sequencing.
     Oral Oncol. 2025;169:107694.
     PubMed     Abstract available
     
     
     
192. HAGREN A, Sjovall J, Brogardh C, Johansson K, et al
     Head and neck lymphedema after radiotherapy - Prevalence, changes and associated factors - a prospective observational cohort study.
     Oral Oncol. 2025;169:107671.
     PubMed     Abstract available
     
     
     
193. HINTZE JM, Cleere E, Timon C, Kinsella J, et al
     The lymph node ratio is a prognostic factor for survival in laryngeal and hypopharyngeal squamous cell carcinoma.
     Oral Oncol. 2025;169:107625.
     PubMed     Abstract available
     
     
     
194. SIQUEIRA JM, Heguedusch D, Cunha MT, de Sousa LG, et al
     Exploring TROP2 expression in oropharyngeal squamous cell carcinoma: Association with prognosis and tumor immune microenvironment composition.
     Oral Oncol. 2025;169:107634.
     PubMed     Abstract available
     
     
     
195. HOUCINE Y, Kedous S, Kamoun S, Methnani A, et al
     Nasopharyngeal low-grade papillary Adenocarcinoma: A rare entity with diagnostic challenges.
     Oral Oncol. 2025;169:107612.
     PubMed     Abstract available
     
     
     
196. KUMARAGURU S, Pandiyan R
     Letter to the Editor: Clinical significance of HPV16 in oropharyngeal cancer: a commentary on recent evidence.
     Oral Oncol. 2025;169:107550.
     PubMed     Abstract available
     
     
     
197. MARUDHUPANDI T
     Letter to the Editor: Prospective study of algorithm-based chemoradioselection to optimize treatment intensity for advanced head and neck cancer.
     Oral Oncol. 2025;170:107731.
     PubMed     Abstract available
     
     
     
198. MARUDHUPANDI T
     Letter to the editor: Development of a novel prognostic signature derived from super-enhancer-associated gene by machine learning in head and neck squamous cell carcinoma.
     Oral Oncol. 2025;170:107730.
     PubMed     Abstract available
     
     
     September 2025
199. MISRA SR, Das R
     Palliative care integration in head and neck Cancer: Bridging the gap between evidence and practice.
     Oral Oncol. 2025;170:107735.
     PubMed    
     
     
     
200. MISRA SR, Das R, Giri M
     Commentary on "pre-treatment PET/CT for head and neck squamous cell carcinoma: secondary analysis of a clinical trial".
     Oral Oncol. 2025;170:107701.
     PubMed    
     
     
     
201. ANNAMALAI A
     Comments on, "Risk factors for fractures after marginal mandibulectomy for head and neck cancer multicentre study".
     Oral Oncol. 2025;170:107716.
     PubMed    
     
     
     
202. ZHANG M
     Comment on "Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma".
     Oral Oncol. 2025;170:107722.
     PubMed    
     
     
     
203. HUANG S, Liao D, Zhu X, Feng Y, et al
     Advancing oral cancer equity in India novel pathways for screening impact.
     Oral Oncol. 2025;170:107696.
     PubMed    
     
     
     
204. LI M, Zhou Y, Cai M
     Letter to the Editor: Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma.
     Oral Oncol. 2025;170:107725.
     PubMed    
     
     
     
205. MISRA SR, Das R
     Esophageal dysmotility in head and neck cancer survivors: a critical step forward and the path ahead!
     Oral Oncol. 2025;170:107718.
     PubMed    
     
     
     
206. DUAN Y
     Comments on: Stroke risk after head and neck cancer diagnosis and treatment in a real-world clinical cohort.
     Oral Oncol. 2025;170:107717.
     PubMed    
     
     
     
207. AL MAQRASHI ZAA, Kartolo A, Meyers BM
     Resectable locally advanced head and neck squamous cell carcinoma: cut first or immune checkpoint inhibitors first?
     Oral Oncol. 2025;170:107704.
     PubMed    
     
     
     
208. CHENG H, Jiang M, Kim S, Moshiri A, et al
     Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma.
     Oral Oncol. 2025;170:107687.
     PubMed     Abstract available
     
     
     
209. MISRA SR, Das R
     Financial instability, insurance, and transportation barriers in oral cancer care: contrasting perspectives between the United States and India.
     Oral Oncol. 2025;169:107692.
     PubMed    
     
     
     
210. SAMUEL M
     Disparities in oral cancer screening in India: reflections on NFHS 5 evidence and pathways forward.
     Oral Oncol. 2025;169:107693.
     PubMed     Abstract available
     
     
     
211. SINDYA J, Rajanathadurai J, Perumal E
     Reflections on "Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients".
     Oral Oncol. 2025;169:107691.
     PubMed    
     
     
     
212. SASIKALA S, Sowmiya A, Usharani N
     Letter to the Editor: Salivary DNA methylation derived estimates of biological Aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
     Oral Oncol. 2025;169:107668.
     PubMed    
     
     
     
213. LUO L, Lu C, Feng H
     Refining SCCUP management: towards safe de-escalation in HPV-positive head and neck cancer-letter on Barrett et al.
     Oral Oncol. 2025;169:107681.
     PubMed    
     
     
     
214. VENKATACHALAM DK, Kanimozhi K
     Letter to the Editor "Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients".
     Oral Oncol. 2025;169:107679.
     PubMed    
     
     
     
215. MISRA SR, Das R
     The imperative of careful selection and novel strategies: Comment on Mrosk et al.'s outcomes of primary chemoradiation for advanced oral cancer.
     Oral Oncol. 2025;169:107676.
     PubMed    
     
     
     
216. LOVETT JT, Westra WH, Roof S, Bakst RL, et al
     Incidence and outcomes of radiation-associated second primary malignancies in HPV-positive oropharyngeal cancer: long-term follow-up of the quarterback de-escalation trials.
     Oral Oncol. 2025;169:107654.
     PubMed     Abstract available
     
     
     
217. KUMAR GN, Sangeetha S
     Comment on "Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients".
     Oral Oncol. 2025 Sep 8:107666. doi: 10.1016/j.oraloncology.2025.107666.
     PubMed    
     
     
     
218. XIAO X, Liu T, Song Y, Lu M, et al
     Evaluation on the prognostic significance of cervical occult metastasis in cN0 glottic laryngeal cancer.
     Oral Oncol. 2025;169:107648.
     PubMed    
     
     
     
219. ZHANG D, Zhang J, Cai M
     Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
     Oral Oncol. 2025;169:107660.
     PubMed    
     
     
     
220. ZHANG D, Zhang P, Cai M
     Letter to the Editor: Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
     Oral Oncol. 2025;169:107661.
     PubMed    
     
     
     
221. DUAN Y
     Letter to the Editor: Oral cancer screening in India: A secondary analysis of disparities using national family health survey data.
     Oral Oncol. 2025;169:107657.
     PubMed    
     
     
     
222. ZHANG D, Zhou Y, Cai M
     Letter to the Editor: Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
     Oral Oncol. 2025;169:107659.
     PubMed    
     
     
     
223. MISRA SR, Das R
     Critical appraisal of "Oral cancer screening in India: A secondary analysis of disparities using national family health survey data".
     Oral Oncol. 2025;169:107653.
     PubMed    
     
     
     
224. PENG X, Xie Y, Liu Y
     Comment on "Prediction of clinical outcomes of immune checkpoint inhibitors in advanced head and neck cancer directly from histopathology slides using inferred transcriptomics".
     Oral Oncol. 2025;169:107644.
     PubMed    
     
     
     
225. BATOOL S, Hansen EE, Sethi RKV, Rettig EM, et al
     Financial instability, insurance, and transportation influence timely head and neck cancer care in the United States: Patient and healthcare worker perspectives.
     Oral Oncol. 2025;169:107607.
     PubMed     Abstract available
     
     
     
226. DUNN LA, Ho AL, Michel LS, Wong W, et al
     A phase 1/1b study of lenvatinib and cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
     Oral Oncol. 2025;169:107524.
     PubMed     Abstract available
     
     
     
227. NOEL CW, Birkenbeuel J, Ozer E, Agrawal A, et al
     Patterns of referral and outcomes in oropharyngeal cancer management.
     Oral Oncol. 2025;168:107602.
     PubMed     Abstract available
     
     
     
228. GILI R, Morbini P, Bossi P
     PD-L1 Expression in head and neck squamous cell carcinoma: qualitative or quantitative assessment? Is that enough or we need something more?
     Oral Oncol. 2025;168:107606.
     PubMed     Abstract available
     
     
     
229. YANG J, Wu W, Liu J, Li J, et al
     Comprehensive integration of single-cell and bulk transcriptome to reveal plasma cell heterogeneity and a prognosis signature in head and neck squamous cell carcinoma.
     Oral Oncol. 2025;168:107595.
     PubMed     Abstract available
     
     
     
230. KLEEBAYOON A, Wiwanitkit V
     Semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD): correspondence.
     Oral Oncol. 2025;169:107645.
     PubMed    
     
     
     
231. BHAGIA P, Mukherjee A, Agarwal T, Giri S, et al
     Stroke risk after head and neck cancer diagnosis and treatment in a Real-World clinical cohort: Running title: Treatment in a Real-World clinical cohort.
     Oral Oncol. 2025;169:107599.
     PubMed     Abstract available
     
     
     August 2025
232. BARRETT TF, Apicelli AJ, Ramadan S, Pipkorn P, et al
     Management of HPV+ head and neck squamous cell carcinoma with unknown primary in the era of treatment de-escalation.
     Oral Oncol. 2025;169:107631.
     PubMed     Abstract available
     
     
     
233. ANSARI E, Carrillo Minulina N, van Es RJJ, Dieleman FJ, et al
     Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients.
     Oral Oncol. 2025;169:107628.
     PubMed     Abstract available
     
     
     
234. DAI Y, Li W
     Comment on "Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD)" by Schroter et al.
     Oral Oncol. 2025;169:107640.
     PubMed    
     
     
     
235. KANA L, Chamma B, Robinette N, Cramer JD, et al
     Pre-treatment PET/CT for head and neck squamous cell carcinoma: secondary analysis of a clinical trial.
     Oral Oncol. 2025;169:107633.
     PubMed     Abstract available
     
     
     
236. HUANG J, Yan X, Wang S, Huang S, et al
     Improvements to the LEF Self-Management study for head and neck cancer survivors - Letter on Deng et al.
     Oral Oncol. 2025;169:107639.
     PubMed    
     
     
     
237. CAO J, Han W, Liu Y
     Letter to the editor: effects of diagnostic delays in head and neck cancer patients presenting to the emergency department.
     Oral Oncol. 2025;169:107624.
     PubMed    
     
     
     
238. HUANG X, Gu X
     Comment on Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study.
     Oral Oncol. 2025;169:107626.
     PubMed    
     
     
     
239. MISRA SR, Das R
     Insights on: "Social health at 5 years after diagnosis in head and neck cancer Survivors".
     Oral Oncol. 2025;169:107637.
     PubMed    
     
     
     
240. BOSSI P, Kiyota N, Mesia R, Rosenberg AJ, et al
     Adverse event profiles and management of cisplatin-based chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a systematic review.
     Oral Oncol. 2025;169:107596.
     PubMed     Abstract available
     
     
     
241. TANG Y, Jin Q, Gan X
     Comment on "Social health at 5 years after diagnosis of head and neck cancer".
     Oral Oncol. 2025;169:107627.
     PubMed    
     
     
     
242. RAHMAN R, Sheikh I, Merchant Y, Mathur A, et al
     Oral cancer screening in India: a secondary analysis of disparities using national family health survey data.
     Oral Oncol. 2025;169:107632.
     PubMed     Abstract available
     
     
     
243. DAI Y, Li WJ
     Comment on "Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: A pilot randomized controlled trial" by Deng J et al.
     Oral Oncol. 2025;169:107613.
     PubMed    
     
     
     
244. CHEN Y, Yan Y
     Comment on "A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus".
     Oral Oncol. 2025;169:107614.
     PubMed    
     
     
     
245. LUO R, Wu J, Zhong W, Ai K, et al
     Letter to the editor - Commentary on "A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus".
     Oral Oncol. 2025;169:107610.
     PubMed    
     
     
     
246. ZHANG J, Liu DM
     Advancing self-management for head and neck cancer-related lymphedema: A promising step forward.
     Oral Oncol. 2025;169:107611.
     PubMed     Abstract available
     
     
     
247. SCHROTER P, Christ LV, Dvornikovich K, Stritzke F, et al
     Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
     Oral Oncol. 2025;169:107604.
     PubMed     Abstract available
     
     
     
248. TANG M, Dougherty M, Worona L, Ramos E, et al
     Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma.
     Oral Oncol. 2025;169:107608.
     PubMed     Abstract available
     
     
     
249. COLAK G, Demir B
     Letter to the Editor: "Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department".
     Oral Oncol. 2025;168:107579.
     PubMed    
     
     
     
250. TOSONI A, Di Nunno V, Carlini A, Gatto L, et al
     The role of systemic therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma progressed to immunotherapy: A systematic review and meta analysis.
     Oral Oncol. 2025;168:107582.
     PubMed     Abstract available
     
     
     
251. ASHOK A, Dimitri S, Plonowska-Hirschfeld K, Wu MP, et al
     Establishing an integrated approach to head and neck cancer treatment and prevention: The Robert Ebert and Greg Stubblefield Head and Neck Tumor Center Model.
     Oral Oncol. 2025;168:107591.
     PubMed     Abstract available
     
     
     
252. LAVANYA K, Sathishkumar K, Nallusamy D
     Letter to the editor: A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
     Oral Oncol. 2025;168:107590.
     PubMed    
     
     
     
253. HONGO T, Hirano Y, Tarutani Y, Omori H, et al
     Prospective study of algorithm-based chemoradioselection to optimize treatment intensity for advanced head and neck cancer.
     Oral Oncol. 2025;168:107585.
     PubMed     Abstract available
     
     
     
254. KOKER G, Ozcelik G
     Comment on: "Cisplatin ototoxicity and hydration schedules''.
     Oral Oncol. 2025;168:107545.
     PubMed    
     
     
     
255. DENG J, Murphy BA, Andersen LP, McMenamin E, et al
     Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: a pilot randomized controlled trial.
     Oral Oncol. 2025;168:107556.
     PubMed     Abstract available
     
     
     
256. SUDARSON J
     Commentary on "molecular features of T and N stage progression in laryngeal cancer".
     Oral Oncol. 2025;168:107587.
     PubMed     Abstract available
     
     
     
257. YU Z, Zhuang Z, Zhao X, Chi H, et al
     Advancing AI-driven pathology in oral cancer: opportunities for enhanced TIL assessment and clinical integration.
     Oral Oncol. 2025;168:107586.
     PubMed    
     
     
     
258. ASHOKKUMAR K
     Letter to the editor - a preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
     Oral Oncol. 2025;168:107580.
     PubMed    
     
     
     
259. KRISHNAN M, Jothishanmugam A, Mari A, Babu S, et al
     Preserving the mandible, protecting the patient: A commentary on fracture risk following marginal mandibulectomy in head and neck cancer.
     Oral Oncol. 2025;168:107575.
     PubMed    
     
     
     
260. MATSUDA Y, Fujioka-Kobayashi M, Tatsumi H, Osako-Sonoyama R, et al
     Factors associated with postoperative oral dysfunction in patients with oral cancer: a structural equation modeling study.
     Oral Oncol. 2025;168:107577.
     PubMed     Abstract available
     
     
     
261. MULARONI F, Marchi F, Gaudioso P, Taboni S, et al
     Selected laryngeal squamous cell carcinomas with laryngeal mobility impairment are suitable for curative larynx-preservation treatment: A multi-institutional study on 406 patients from the ARYFIX collaborative group.
     Oral Oncol. 2025;167:107466.
     PubMed     Abstract available
     
     
     
262. MORES AL, Lima de Araujo CA, de Freitas Busnardo F, Cardili L, et al
     Cutaneous metastasis of oropharyngeal squamous cell carcinoma: A case report.
     Oral Oncol. 2025;167:107438.
     PubMed     Abstract available
     
     
     
263. SEDASSARI BT, Celin MF, Pigatti FM
     SMARCB1-deficient sinonasal carcinoma with oral involvement: A potential mimicker of salivary-type carcinomas.
     Oral Oncol. 2025;167:107435.
     PubMed     Abstract available
     
     
     
264. TONSBEEK AM, Hundepool CA, van der Oest M, Offerman MPJ, et al
     Life following total laryngectomy: mixed-model analyses of longitudinal patient-reported outcomes in a prospective cohort.
     Oral Oncol. 2025;167:107431.
     PubMed     Abstract available
     
     
     
265. PERYASSU BC, Nicolau-Neto P, da Costa EWE, Santos IC, et al
     Assessing the prognostic significance and predictive features of cervical occult metastasis in glottic laryngeal squamous cell carcinoma.
     Oral Oncol. 2025;167:107429.
     PubMed     Abstract available
     
     
     
266. DOLL C, Hofmann E, Trelinska-Finger A, Heiland M, et al
     Benefit from adjuvant radiotherapy in early-stage oral cavity and oropharyngeal cancer with solitary ipsilateral lymph node metastasis - A population-based study on German cancer registry data.
     Oral Oncol. 2025;167:107384.
     PubMed     Abstract available
     
     
     
267. GUZZO M, Bianchi R, Colombo S, Santamato F, et al
     Mandibular swing approach: 25 years of experience at Istituto Nazionale Tumori of Milan.
     Oral Oncol. 2025;167:107405.
     PubMed     Abstract available
     
     
     
268. TONG JY, Brimanson K, Moyer K, Wolf J, et al
     Margin analysis of radical tonsillectomy specimens following transoral robotic surgery.
     Oral Oncol. 2025;167:107403.
     PubMed     Abstract available
     
     
     
269. LUNA-ORTIZ K, Guillen-Hernandez GA, Cano-Valdez AM, Alvarez-Avitia MA, et al
     Poorly differentiated ceruminous adenocarcinoma of the external auditory canal: Letter to the editor.
     Oral Oncol. 2025;168:107544.
     PubMed    
     
     
     
270. JENNIFER LG, Larnaudie A, Bene MC, Cocherie T, et al
     Relationships between oral microbiome and head and neck squamous cell carcinoma: a systematic review.
     Oral Oncol. 2025;168:107571.
     PubMed     Abstract available
     
     
     
271. HUMBERT M, Perreard M, Licaj I, Bouhnik AD, et al
     Social health at 5 years after diagnosis of head and neck cancer.
     Oral Oncol. 2025;168:107567.
     PubMed     Abstract available
     
     
     July 2025
272. ELIA A, Tirosh O, Dinstag G, Gugel L, et al
     Prediction of clinical outcomes of immune checkpoint inhibitors in advanced head and neck cancer directly from histopathology slides using inferred transcriptomics.
     Oral Oncol. 2025;168:107536.
     PubMed     Abstract available
     
     
     
273. LI Y, Xiao L, Xie R
     Mitigating survival disparities in head and neck cancer: urgent need to reduce ED-based biopsy delays.
     Oral Oncol. 2025;168:107549.
     PubMed    
     
     
     
274. SHARFUNNISA SH
     Letter to the editor "reframing nutritional support in head and neck cancer: insights from a prospective cohort study".
     Oral Oncol. 2025;168:107563.
     PubMed    
     
     
     
275. ZHANG D, Cai M
     Letter to the Editor: A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
     Oral Oncol. 2025;168:107558.
     PubMed    
     
     
     
276. RAJASEKAR A
     Letter to the Editor: HCV infection in head and neck cancer patients: Implications for screening and prognosis in a low prevalence setting.
     Oral Oncol. 2025;168:107561.
     PubMed     Abstract available
     
     
     
277. HIEROMNIMON HM, Trzcinska A, Wen FT, Howard FM, et al
     Corrigendum to "Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas". [Oral Oncol. 163 (2025) 107207].
     Oral Oncol. 2025 Jul 27:107510. doi: 10.1016/j.oraloncology.2025.107510.
     PubMed    
     
     
     
278. KRISHNAN M, Babu S
     Commentary on Lee et al: From crisis to diagnosis: redefining the emergency department's role in head and neck cancer detection.
     Oral Oncol. 2025;168:107546.
     PubMed    
     
     
     
279. PENG J, Liang Z, Wang J, Wang G, et al
     Comment on effects of diagnostic delays in head and neck cancer patients presenting to the emergency department.
     Oral Oncol. 2025;168:107537.
     PubMed    
     
     
     
280. KRISHNAN M, Babu S
     Letter to the editor: redefining surgical paradigms in isthmic papillary thyroid carcinoma: a timely reappraisal.
     Oral Oncol. 2025;168:107562.
     PubMed    
     
     
     
281. NARENKUMAR J, Parthipan P
     Letter to the Editor: Impact of the COVID-19 pandemic on diagnosis and disease stage in HPV-positive oropharyngeal cancer: insights and future directions.
     Oral Oncol. 2025;168:107541.
     PubMed     Abstract available
     
     
     
282. D'ANDREA C, Marhic A, Leveque E, Thureau S, et al
     Risk factors for fractures after marginal mandibulectomy for head and neck cancer multicentre study.
     Oral Oncol. 2025;168:107512.
     PubMed     Abstract available
     
     
     
283. BABU S, Krishnan M, Ravi PS
     "Commentary on: Long-term health-related quality of life in oral cancer survivors following microvascular tongue reconstruction".
     Oral Oncol. 2025;168:107552.
     PubMed    
     
     
     
284. KRISHNAN M, Chawla KK, Babu S, D S, et al
     Letter to the editor: Molecular stratification in papillary thyroid carcinoma: Should RET fusions redefine aggressiveness in the post-BRAF era?
     Oral Oncol. 2025;168:107543.
     PubMed    
     
     
     
285. MORCOM CR, Williams CMD, Al-Qadami G, Vieyra CP, et al
     The biological mechanisms underpinning nutritional and health-related consequences of mucositis in head and neck cancer - A review.
     Oral Oncol. 2025;168:107548.
     PubMed    
     
     
     
286. ARULMOORTHY MP
     Navigating the diagnostic delay: optimizing timely biopsy and integrating NIR-based technologies for head and neck cancer.
     Oral Oncol. 2025;168:107518.
     PubMed     Abstract available
     
     
     
287. SHARFUNNISA SH, Rahmathullah A
     Letter to the editor "Integrating nutritional profiling into immunotherapy: A modifiable predictor of outcomes in head and neck Cancer".
     Oral Oncol. 2025;168:107539.
     PubMed    
     
     
     
288. BABU S, Solomon A, Krishnan M
     Commentary on "Massive nasal bleeding in nasopharyngeal carcinoma: Incidence, risk predictors, and survival impact".
     Oral Oncol. 2025;168:107528.
     PubMed    
     
     
     
289. JEYARAJ G
     Commentary on, "Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department".
     Oral Oncol. 2025;168:107532.
     PubMed    
     
     
     
290. ABILAJI S, Parthipan P
     Letter to the Editor: Evaluating the risk-modifying effects of HSV-1 and HSV-2 on head and neck cancer in relation to tobacco, alcohol, and HPV-16.
     Oral Oncol. 2025;168:107516.
     PubMed     Abstract available
     
     
     
291. CHAWLA JPS, Madan GK
     Comment on "Current status of circulating tumour DNA and circulating cell alterations in HPV-associated head and neck cancer".
     Oral Oncol. 2025;168:107526.
     PubMed    
     
     
     
292. ZHU J, Xu J, Qu H, Hao J, et al
     A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
     Oral Oncol. 2025;168:107511.
     PubMed     Abstract available
     
     
     
293. LEE MY, Huynh JD, Kim DD, Sunwoo JB, et al
     Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department.
     Oral Oncol. 2025;168:107467.
     PubMed     Abstract available
     
     
     
294. YANG Z, Lin B, Xie R
     Microvascular tongue reconstruction in oral cancer: Long-term functional outcomes and quality of life considerations.
     Oral Oncol. 2025;167:107490.
     PubMed    
     
     
     
295. ZHANG Y, Liang R, Lai P
     Comment on "The association between health-related quality of life and five-year overall survival among head and neck cancer patients: A prospective cohort study".
     Oral Oncol. 2025;167:107491.
     PubMed    
     
     
     
296. JEYARAJ G
     Commentary on, "Transoral endoscopic thyroidectomy vestibular approach for pT1b papillary thyroid carcinoma: Surgical and oncological outcomes.".
     Oral Oncol. 2025;167:107487.
     PubMed    
     
     
     
297. RAJATHIRAJAN SD
     Commentary on, "Impact of HIV status on overall survival in head and neck cancers by anatomical site and stage: A multi-center cohort study".
     Oral Oncol. 2025;167:107483.
     PubMed    
     
     
     
298. JEYARAJ G
     Commentary on, "Massive nasal bleeding in nasopharyngeal Carcinoma: Incidence, risk Predictors, and survival impact.".
     Oral Oncol. 2025;167:107488.
     PubMed    
     
     
     
299. CHENG HS, Lin TY, Twu CW, Lin PJ, et al
     Corrigendum to "Massive nasal bleeding in nasopharyngeal carcinoma: incidence, risk predictors, and survival impact" [Oral Oncol. 167 (2025) 107456].
     Oral Oncol. 2025 Jul 4:107465. doi: 10.1016/j.oraloncology.2025.107465.
     PubMed    
     
     
     
300. RAJATHIRAJAN SD
     Commentary on, "Computed tomography radiomics-based cross-sectional detection of mandibular osteoradionecrosis in head and neck cancer survivors".
     Oral Oncol. 2025;167:107472.
     PubMed    
     
     
     
301. HU A, Wen X, Tian J, Wang Z, et al
     RET fusion rather than BRAF mutation confers a higher risk of aggressiveness and recurrence in papillary thyroid carcinoma.
     Oral Oncol. 2025;167:107464.
     PubMed     Abstract available
     
     
     
302. RIJKEN JA, de Ridder M, Devriese LA, Breimer GE, et al
     Long-term survival after multimodal treatment of sinonasal NUT carcinoma: a case report.
     Oral Oncol. 2025;166:107392.
     PubMed     Abstract available
     
     
     
303. RONDI P, Mattavelli D, Rampinelli V, Schreiber A, et al
     The role of volumetry in sinonasal cancer response assessment to induction chemotherapy, results from two phase II non-randomized controlled prospective multicentric trials: SINTART-1 and SINTART-2.
     Oral Oncol. 2025;166:107388.
     PubMed     Abstract available
     
     
     
304. SOMAY E, Bascil S, Topkan E, Selek U, et al
     Re: "Computed tomography radiomics-based cross-sectional detection of mandibular osteoradionecrosis in head and neck cancer survivors" by Kamel et al.
     Oral Oncol. 2025;167:107457.
     PubMed    
     
     
     June 2025
305. MALGAVE DS, Hartman CM, Kramer JR, Richardson PA, et al
     Impact of HIV status on overall survival in head and neck cancers by anatomical site and stage: A multi-center cohort study.
     Oral Oncol. 2025;167:107446.
     PubMed     Abstract available
     
     
     
306. ABILAJI S, Narenkumar J
     Letter to the Editor: Enhancing early detection of HPV associated oropharyngeal cancer: a comparative study of NGS, ddPCR, and qPCR.
     Oral Oncol. 2025 Jun 27:107461. doi: 10.1016/j.oraloncology.2025.107461.
     PubMed     Abstract available
     
     
     
307. EICKELSCHULTE S, Starus A, Murray DH, Keyser KA, et al
     Analytical and clinical performance validation of HPV-SEQ, a novel NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA.
     Oral Oncol. 2025;167:107445.
     PubMed     Abstract available
     
     
     
308. RAJATHIRAJAN SD
     Commentary on, "Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA and AJCC staging".
     Oral Oncol. 2025;167:107453.
     PubMed    
     
     
     
309. CHENG HS, Lin TY, Twu CW, Lin PJ, et al
     Massive nasal bleeding in nasopharyngeal Carcinoma: Incidence, risk Predictors, and survival impact: Running title: Massive nasal bleeding in NPC.
     Oral Oncol. 2025;167:107456.
     PubMed     Abstract available
     
     
     
310. DAUNGSUPAWONG H, Wiwanitkit V
     Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: Comment.
     Oral Oncol. 2025;167:107454.
     PubMed    
     
     
     
311. SAMUEL CHAN SW, Amer Al Maqrashi ZA, Kim DH, Choi D, et al
     Induction chemotherapy and immunotherapy followed by chemo-radiotherapy in incurable advanced head and neck squamous cell carcinoma: A case-series.
     Oral Oncol. 2025;167:107439.
     PubMed    
     
     
     
312. NGO DQ, Truong DS, Le DT, Hoang TM, et al
     Transoral endoscopic thyroidectomy vestibular approach for pT1b papillary thyroid carcinoma: surgical and oncological outcomes.
     Oral Oncol. 2025;167:107406.
     PubMed     Abstract available
     
     
     
313. ARAUJO M, Bouassaly J, Farshadi F, Hier M, et al
     Current status of circulating tumor DNA and circulating cell alterations in HPV-associated head and neck cancer.
     Oral Oncol. 2025;167:107417.
     PubMed     Abstract available
     
     
     
314. KAMEL S, Humbert-Vidan L, Kaffey Z, Mirbahaeddin S, et al
     Computed tomography radiomics-based cross-sectional detection of mandibular osteoradionecrosis in head and neck cancer survivors.
     Oral Oncol. 2025;167:107337.
     PubMed     Abstract available
     
     
     
315. MAK CH, Cao LM, Luo HY, Zhou K, et al
     Postoperative complications of neck dissection for head and neck squamous cell carcinoma: a systematic review and meta-analysis.
     Oral Oncol. 2025;167:107430.
     PubMed     Abstract available
     
     
     
316. YANG X, Li R
     Reconsidering the prognostic value of HRQOL in head and neck cancer.
     Oral Oncol. 2025;167:107421.
     PubMed    
     
     
     
317. YAN Y, Wang Z, Sun Y
     Comment on: Margins do not impact recurrence and survival in advanced laryngeal cancer-A retrospective cohort analysis.
     Oral Oncol. 2025;167:107427.
     PubMed    
     
     
     
318. LIANG YJ, Luo MJ, Wen DX, Wang P, et al
     Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA and AJCC staging.
     Oral Oncol. 2025;167:107404.
     PubMed     Abstract available
     
     
     
319. KIM MJ, Koo BS, Cho KJ, Lee SH, et al
     Health-related quality-of-life assessment in patients with oropharyngeal cancer: A comparison of EQ-5D-5L and EORTC instruments.
     Oral Oncol. 2025;165:107342.
     PubMed     Abstract available
     
     
     
320. GARSET-ZAMANI M, Makouei F, Agander TK, Lelkaitis G, et al
     Feasibility of 3D ultrasound for intraoperative tumor margin assessment in transoral robotic surgery for oropharyngeal squamous cell carcinoma: A pilot study.
     Oral Oncol. 2025;165:107330.
     PubMed     Abstract available
     
     
     
321. KUMARI S, Mishra S, Ali W, Singh US, et al
     Implication of circulating miRNAs as potential diagnostic biomarker in oropharyngeal squamous cell Carcinoma: Association with Human Papilloma Virus.
     Oral Oncol. 2025;165:107305.
     PubMed     Abstract available
     
     
     
322. JANG HB, Lee DH, Lim SC
     Treatment outcomes of sinonasal adenoid cystic carcinoma: a single-center experience.
     Oral Oncol. 2025;165:107317.
     PubMed     Abstract available
     
     
     
323. CHELVARAJAH RC, Liu Y, Su J, Abdalaty AH, et al
     Factors associated with detection of oligometastatic recurrence and outcome following definitive (Chemo)radiotherapy for oropharyngeal carcinoma.
     Oral Oncol. 2025;165:107310.
     PubMed     Abstract available
     
     
     May 2025
324. HINTZE JM, Cleere E, Soo A, Timon C, et al
     Margins do not impact recurrence and survival in advanced laryngeal cancer - A retrospective cohort analysis.
     Oral Oncol. 2025;167:107402.
     PubMed     Abstract available
     
     
     
325. BAIJU DC, Ravi J, Sarma M, Sureshan M, et al
     Detection of hotspot mutations in oral cancer through Ion AmpliSeq cancer hotspot panel v.2.0: A circulating DNA fragmentomics approach in the Northeast Indian population.
     Oral Oncol. 2025;166:107387.
     PubMed     Abstract available
     
     
     
326. JEYARAJ G
     Commentary on, "The association between health-related quality of life and five-year overall survival among head and neck cancer patients: A prospective cohort study".
     Oral Oncol. 2025;166:107401.
     PubMed    
     
     
     
327. LIU X, Xue S
     Comment on: Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations.
     Oral Oncol. 2025;166:107368.
     PubMed    
     
     
     
328. VERDONCK-DE LEEUW IM, Lissenberg-Witte BI, de Bree R, Buffart LM, et al
     The association between health-related quality of life and five-year overall survival among head and neck cancer patients: A prospective cohort study.
     Oral Oncol. 2025;166:107367.
     PubMed     Abstract available
     
     
     
329. OLSON B, Bogan A, Abdel-Halim CN, Rolle-McFarland D, et al
     Identification of clinical and pathologic features associated with extranodal extension in patients with HPV-mediated oropharyngeal squamous cell carcinoma.
     Oral Oncol. 2025;166:107308.
     PubMed     Abstract available
     
     
     
330. TONSBEEK AM, van der Lely JN, Bulstra L, Venema J, et al
     Long-term health-related quality of life in oral cancer survivors following microvascular tongue reconstruction.
     Oral Oncol. 2025;166:107363.
     PubMed     Abstract available
     
     
     
331. MALI SB
     Corrigendum to "Review of STAT3 (Signal Transducers and Activators of Transcription) in head and neck cancer" [Oral Oncol. 51 (2015) 565-569].
     Oral Oncol. 2025 May 10:107357. doi: 10.1016/j.oraloncology.2025.107357.
     PubMed    
     
     
     
332. MALI SB
     Corrigendum to "RNA interference in oral cancer" [Oral Oncol. 51 (2015) e2-e3].
     Oral Oncol. 2025 May 9:107358. doi: 10.1016/j.oraloncology.2025.107358.
     PubMed    
     
     
     
333. SHAIKH N, Pandey M, Manna S, Gawde J, et al
     Evaluating the prognostic value of tumor-derived circulating endothelial cells and their progenitors in platinum-refractory oral cancer patients for response to triple metronomic therapy.
     Oral Oncol. 2025;165:107346.
     PubMed     Abstract available
     
     
     
334. COSTANTINO A, Haughey BH, Alamoudi U, Magnuson JS, et al
     Prognostic significance of distant metastasis site at diagnosis in HPV-related oropharyngeal cancer.
     Oral Oncol. 2025;165:107361.
     PubMed     Abstract available
     
     
     
335. ONAGA R, Enokida T, Kuno H, Hiyama T, et al
     Significance of imaging-detected extranodal extension in locally advanced squamous cell carcinoma of the head and neck treated with induction chemotherapy followed by chemoradiotherapy.
     Oral Oncol. 2025;165:107351.
     PubMed     Abstract available
     
     
     
336. ZHU X, Xu H, Zhao Y, Diao W, et al
     Single-cell transcriptomics reveal the effects of chemoimmunotherapy on hypopharyngeal cancer and its tumor microenvironment.
     Oral Oncol. 2025;165:107347.
     PubMed     Abstract available
     
     
     
337. PEI Y, Yang Z, Mao Y, Chen X, et al
     Evolving dynamics in clinical trials for oral cancer: Trends, treatment modalities, and future directions.
     Oral Oncol. 2025;165:107333.
     PubMed     Abstract available
     
     
     
338. XIAO X, Liu T, Lu M, Song Z, et al
     Comment on the role of lymph node level ratio in predicting prognosis of pN1 head and neck squamous cell carcinoma.
     Oral Oncol. 2025;165:107344.
     PubMed    
     
     
     
339. CHENNAREDDY S, Chen S, Levinson C, Genden EM, et al
     Circulating tumor DNA in human papillomavirus-associated oropharyngeal cancer management: A systematic review.
     Oral Oncol. 2025;164:107262.
     PubMed     Abstract available
     
     
     
340. MARCHI F, Del Bon F, Chu F, Sampieri C, et al
     Refining prognostic subcategories in intermediate-advanced glottic cancer: A multicentric study on 637 patients treated by transoral laser microsurgery.
     Oral Oncol. 2025;164:107264.
     PubMed     Abstract available
     
     
     
341. CANALI L, Russo E, Pangallo S, Bussu F, et al
     Regional disease control in nasal vestibule squamous cell carcinoma: Systematic review and meta-analysis.
     Oral Oncol. 2025;164:107270.
     PubMed     Abstract available
     
     
     
342. MOTTA G, Magno C, Castagna L, De Berardinis T, et al
     Endoscope-assisted trans-oral approach (EATA) to remove a rare pleomorphic adenoma of the nasopharynx.
     Oral Oncol. 2025;164:107260.
     PubMed     Abstract available
     
     
     
343. BEDDOK A, Popovtzer A, Calugaru V, Fontaine M, et al
     Proton therapy for primary and recurrent HPV-related oropharyngeal cancer.
     Oral Oncol. 2025;165:107309.
     PubMed     Abstract available
     
     
     April 2025
344. MALI SB
     Corrigendum to "Proteomics for oral cancer" [Oral Oncol. 50(11) (2014) e67].
     Oral Oncol. 2025 Apr 30:107338. doi: 10.1016/j.oraloncology.2025.107338.
     PubMed    
     
     
     
345. CITRO S, Ghiani L, Doni M, Miccolo C, et al
     HPV-mediated PARP1 regulation and drug sensitization in head and neck cancer.
     Oral Oncol. 2025;165:107307.
     PubMed     Abstract available
     
     
     
346. SILVA CUNHA JL
     Comment on "Histological tumor necrosis predicts decreased survival after neoadjuvant chemotherapy in head and neck squamous cell carcinoma".
     Oral Oncol. 2025;165:107336.
     PubMed    
     
     
     
347. AL FADEL AM, Jakobsen KK, Jensen LH, Carlander AF, et al
     The epidemiological trends and survival of HPV-related oropharyngeal cancer other than tonsils and base of tongue - a systematic review and meta-analysis.
     Oral Oncol. 2025;165:107311.
     PubMed     Abstract available
     
     
     
348. ARDILA CM
     Enhancing the scope and impact of photobiomodulation research in head and neck cancer therapy.
     Oral Oncol. 2025;165:107303.
     PubMed    
     
     
     
349. JEYARAJ G
     Commentary on, "Molecular features of T and N stage progression in laryngeal cancer.".
     Oral Oncol. 2025;165:107331.
     PubMed    
     
     
     
350. BARCELONA MVN, Waldron J, Sullivan BO, Su J, et al
     Outcomes following IMRT alone in head and neck squamous cell carcinoma ordinarily managed with concurrent chemo-radiotherapy.
     Oral Oncol. 2025;165:107299.
     PubMed     Abstract available
     
     
     
351. YAO CMKL, Hueniken K, Huang SH, Liu G, et al
     Development of a patient reported outcomes based machine learning model to predict recurrences in head and neck cancer.
     Oral Oncol. 2025;165:107304.
     PubMed     Abstract available
     
     
     
352. JEYARA G
     Commentary on, "Risk factors and a risk assessment model for venous thromboembolism in head and neck cancer surgery.".
     Oral Oncol. 2025;165:107320.
     PubMed    
     
     
     
353. ZHOU P, Zhu Y, Xu B, Jiang X, et al
     Cavernous sinus syndrome in a patient with occult nasopharyngeal carcinoma: A diagnostic challenge.
     Oral Oncol. 2025;165:107316.
     PubMed     Abstract available
     
     
     
354. COSTANTINO A, Sampieri C, Haughey BH, Alamoudi U, et al
     Adjuvant treatment in elderly patients undergoing transoral surgery for HPV-related oropharyngeal cancer.
     Oral Oncol. 2025;165:107312.
     PubMed     Abstract available
     
     
     
355. KOSKENNIEMI AR, Huusko T, Routila J, Jalkanen S, et al
     Histological tumor necrosis predicts decreased survival after neoadjuvant chemotherapy in head and neck squamous cell carcinoma.
     Oral Oncol. 2025;165:107287.
     PubMed     Abstract available
     
     
     
356. JEYARAJ G
     Commentary on, "Effect of Enhanced Recovery After Radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial".
     Oral Oncol. 2025;165:107302.
     PubMed    
     
     
     
357. LI N, Zeng PYF, Kim HAJ, Karimi A, et al
     Molecular features of T and N stage progression in laryngeal cancer.
     Oral Oncol. 2025;165:107283.
     PubMed     Abstract available
     
     
     
358. BURGER AVM, Koot MA, van Balen DEM, Schaeffers AWMA, et al
     Comparison of cisplatin-induced hearing loss in different durations of infusion and volume of hydration schedules in head and neck squamous cell carcinoma patients treated with cisplatin-based chemoradiation.
     Oral Oncol. 2025;164:107246.
     PubMed     Abstract available
     
     
     
359. HANNA GJ, Zheng D, Gao W, Hair GM, et al
     Corrigendum to "PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S." [Oral Oncol. 161 (2025) 107146].
     Oral Oncol. 2025 Apr 11:107292. doi: 10.1016/j.oraloncology.2025.107292.
     PubMed    
     
     
     
360. MA J, Brooks C, Tasoulas J, Wind LS, et al
     Revisiting the use of capecitabine in the era of immunotherapy: Efficacy as second-line and later therapy in recurrent/metastatic head and neck squamous cell carcinoma.
     Oral Oncol. 2025;164:107293.
     PubMed    
     
     
     
361. SLATER NN, Herberger L, Farsi S, Rogers AL, et al
     Assessing barriers to adjuvant therapy among patients with head and neck cancer in Arkansas.
     Oral Oncol. 2025;164:107290.
     PubMed     Abstract available
     
     
     
362. XIAO J, You M, Song Y, Gao R, et al
     Risk factors and a risk assessment model for venous thromboembolism in head and neck cancer surgery.
     Oral Oncol. 2025;164:107288.
     PubMed     Abstract available
     
     
     
363. VIANNA CAMOLESI GC, Prado-Pena IB, Gomez-Caamano A, Victoria-Fernandez C, et al
     Photobiomodulation for the prevention of oral side effects secondary to head and neck cancer therapy: results of a randomised, single-blind clinical trial.
     Oral Oncol. 2025;164:107266.
     PubMed     Abstract available
     
     
     
364. JEYARAJ G
     Commentary on, "Evaluation of a comprehensive set of normal tissue complication probability models for patients with head and neck cancer in an international cohort".
     Oral Oncol. 2025;164:107285.
     PubMed    
     
     
     
365. ROSING F, Plath M, Proctor T, Hofler D, et al
     Post-treatment monitoring of surgically treated oropharyngeal squamous cell carcinoma patients using human papillomavirus cell-free DNA.
     Oral Oncol. 2025;163:107225.
     PubMed     Abstract available
     
     
     March 2025
366. LIN N, Zhou X, Wang Y, Zhou J, et al
     Effect of enhanced recovery after radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial.
     Oral Oncol. 2025;164:107269.
     PubMed     Abstract available
     
     
     
367. JEYARAJ G
     Commentary on, "Thyroid volumes after intensity-modulated radiotherapy as predictors of radiation-induced hypothyroidism in nasopharyngeal carcinoma: A retrospective study".
     Oral Oncol. 2025;163:107256.
     PubMed    
     
     
     
368. ARDILA CM, Yadalam PK
     AI-driven histopathologic insights in HPV-positive head and neck squamous cell carcinomas.
     Oral Oncol. 2025;163:107261.
     PubMed    
     
     
     
369. MATHEW JM, Busca I, Baskurt Z, Giuliani M, et al
     Changes in unmet needs after treatment for head and neck cancers - A prospective longitudinal cohort study.
     Oral Oncol. 2025;163:107250.
     PubMed     Abstract available
     
     
     
370. DONG Z, Wang GY, Qin GJ, Dai DY, et al
     Thyroid volumes after intensity-modulated radiotherapy as predictors of radiation-induced hypothyroidism in nasopharyngeal carcinoma: A retrospective study.
     Oral Oncol. 2025;163:107223.
     PubMed     Abstract available
     
     
     
371. LORENZ FJ, Kharouta M, Mahase SS, Goyal N, et al
     Hospital-Based Registry Analysis of Staging Efficacy and Proposed Staging Subclassification for Stage I HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
     Oral Oncol. 2025;163:107251.
     PubMed     Abstract available
     
     
     
372. PETRELLI F, Lorini L, Paderno A, Carioli D, et al
     Treatment of primary tumor in metastatic head and neck Carcinoma: A systematic review and Meta-Analysis.
     Oral Oncol. 2025;163:107248.
     PubMed     Abstract available
     
     
     
373. HIEROMNIMON HM, Trzcinska A, Wen FT, Howard FM, et al
     Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas.
     Oral Oncol. 2025;163:107207.
     PubMed     Abstract available
     
     
     
374. GAZZINI L, Festa BM, Calabrese L
     Elective neck dissection: Are we bound to outdated concepts?
     Oral Oncol. 2025;163:107245.
     PubMed    
     
     
     
375. WU WJ, An PG, Liu Q, Zhang ZQ, et al
     Neoadjuvant chemoimmunotherapy brings superior quality of life of patients with locally advanced oral or oropharyngeal cancer: A propensity score-matched analysis.
     Oral Oncol. 2025;162:107218.
     PubMed     Abstract available
     
     
     
376. YANG F, Peng W, Wei H, Li X, et al
     Model-free parameters derived from intravoxel inherent motion combined with tumor aggressiveness indicators in predicting 5-year treatment outcome in NPC.
     Oral Oncol. 2025;162:107187.
     PubMed     Abstract available
     
     
     
377. YE Z, Li X, Xie F, Sun J, et al
     A single-cell sequencing-based analysis of a 13-year-old with maxillary sinus NUT carcinoma.
     Oral Oncol. 2025;162:107185.
     PubMed     Abstract available
     
     
     
378. CHARLTON A, Mughal Z, Sharin F, Sahota RB, et al
     Prevalence of synchronous bilateral/contralateral tonsil carcinoma: A systematic review and meta-analysis.
     Oral Oncol. 2025;162:107180.
     PubMed     Abstract available
     
     
     
379. DE VETTE SPM, van Rijn-Dekker MI, Van den Bosch L, Keijzer K, et al
     Evaluation of a comprehensive set of normal tissue complication probability models for patients with head and neck cancer in an international cohort.
     Oral Oncol. 2025;163:107224.
     PubMed     Abstract available
     
     
     
380. MIYAGUCHI J, Shiga K, Katagiri K, Saito D, et al
     Efficacy of boron neutron capture therapy (BNCT) for patients with oral cancer.
     Oral Oncol. 2025;163:107228.
     PubMed     Abstract available
     
     
     February 2025
381. WICZUK-WICZEWSKA M, Bernaciak J, Nogal P, Bugaj A, et al
     Squamous cell carcinoma in the posterior larynx: A rare localization of supraglottic T1 laryngeal cancer. Case report.
     Oral Oncol. 2025;163:107227.
     PubMed     Abstract available
     
     
     
382. JEYARAJ G
     Letter to the editor, "Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell carcinoma: A multicenter, open-label, single-arm, phase 1b study.".
     Oral Oncol. 2025;163:107231.
     PubMed    
     
     
     
383. TINO RB, Roach MA, Fuentes GD, Agrawal A, et al
     Response to recent comments on "Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy".
     Oral Oncol. 2025;162:107220.
     PubMed    
     
     
     
384. MEEKER BS MO, Katragadda A, Alsavaf MB, Birkenbeuel J, et al
     Dysphagia in head and neck cancer patients with evidence of esophageal dysmotility on manometry.
     Oral Oncol. 2025;162:107219.
     PubMed     Abstract available
     
     
     
385. YANG H, Sun P, Wang Y, Wang X, et al
     Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell Carcinoma: A Multicenter, Open-label, Single-arm, phase 1b study.
     Oral Oncol. 2025;162:107211.
     PubMed     Abstract available
     
     
     
386. IQBAL MS, West N, Kovarik J, Jackson M, et al
     Effective, efficient palliative radiotherapy for advanced head and neck cancer: Real world data using 25 Gy in 5 fractions.
     Oral Oncol. 2025;162:107214.
     PubMed    
     
     
     
387. KHAN A, Pillay M, Bipath R, Msimang M, et al
     Evolution of testing for the diagnosis of human papillomavirus (HPV) status in head and neck squamous cell carcinoma: Where from and where to?
     Oral Oncol. 2025;162:107208.
     PubMed     Abstract available
     
     
     
388. MO Y, Wei Y, Liang L, Wu T, et al
     Clinical significance of post-chemoradiotherapy 2-[(18)F]FDG PET/CT response in locally advanced nasopharyngeal carcinoma: A real-world study.
     Oral Oncol. 2025;161:107160.
     PubMed     Abstract available
     
     
     
389. LOUBIERES C, Baudouin R, Circiu M, Couineau F, et al
     Functional and oncological outcomes of transoral laser versus robotic surgery in supraglottic squamous cell carcinoma.
     Oral Oncol. 2025;161:107178.
     PubMed     Abstract available
     
     
     
390. PERSHAD AR, Ferraro T, Shaver TB, Lee E, et al
     Pathologic responses and clinical outcomes with neoadjuvant doublet chemotherapy for newly diagnosed, surgically-resectable p16-positive oropharyngeal cancer.
     Oral Oncol. 2025;161:107139.
     PubMed     Abstract available
     
     
     
391. FENG ZK, Wu WB, Zou RC, Zhang JZ, et al
     Postradiotherapy nasopharyngeal necrosis with granulation mass: Insights from a multicentre study.
     Oral Oncol. 2025;161:107170.
     PubMed     Abstract available
     
     
     
392. LYU SI, Fretter C, Eckel HNC, Knipper K, et al
     High expression of H2AX/gamma-H2AX is associated with distinct biological pathway alterations and shorter survival in oropharyngeal squamous cell carcinoma.
     Oral Oncol. 2025;161:107171.
     PubMed     Abstract available
     
     
     
393. KWON JJ, Milner TD, Kurten C, Pang EH, et al
     Towards transcervical ultrasound-guided transoral robotic surgery.
     Oral Oncol. 2025;161:107167.
     PubMed     Abstract available
     
     
     
394. SUCHAN M, Wuerdemann N, Wagner S, Langer C, et al
     Histological and genetic criteria define a clinically relevant subgroup of HPV-positive oropharyngeal carcinoma.
     Oral Oncol. 2025;162:107209.
     PubMed     Abstract available
     
     
     January 2025
395. WENGER TA, Gao J, Nurimba M, Phung PG, et al
     Palliative care utilization among head and neck cancer patients: A population-based analysis.
     Oral Oncol. 2025;162:107205.
     PubMed     Abstract available
     
     
     
396. CHEN L, Fang R, Cai Z, Huang B, et al
     CD271(high) cancer stem cells regulate macrophage polarization in head and neck squamous cell carcinoma.
     Oral Oncol. 2025;162:107181.
     PubMed     Abstract available
     
     
     
397. YIN Z, Zhao H, Zhu C, Fang J, et al
     Comment on: Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy.
     Oral Oncol. 2025;161:107195.
     PubMed    
     
     
     
398. JIANG H, Zhou L, Zhao T, Zou G, et al
     Anaplastic thyroid carcinoma in a 43-year-old female confirmed by metastatic lymph node pathology: A case report.
     Oral Oncol. 2025;161:107192.
     PubMed    
     
     
     
399. JIANG H, Zhou L, Zou G, Zhang H, et al
     Synchronous papillary and medullary thyroid carcinoma with distinct genetic mutations: A case report.
     Oral Oncol. 2025;161:107191.
     PubMed    
     
     
     
400. LI MH, Hu YJ, Shan HM, Gao XL, et al
     The role of lymph node level ratio in predicting prognosis and the benefits of postoperative radiotherapy in patients with pathological N1 stage head and neck squamous cell carcinoma.
     Oral Oncol. 2025;161:107193.
     PubMed     Abstract available
     
     
     
401. HUTTINGER ZM, Gogineni E, Baliga S, Blakaj DM, et al
     Circulating tumor DNA determines induction chemotherapy response in HPV associated oropharyngeal squamous cell carcinoma: A pilot study.
     Oral Oncol. 2025;161:107179.
     PubMed     Abstract available
     
     
     
402. TOPKAN E, Somay E, Selek U
     Commentary on "Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF".
     Oral Oncol. 2025;161:107175.
     PubMed    
     
     
     
403. SENYUREK S, Durankus NK, Selek U, Topkan E, et al
     Comment on "The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma".
     Oral Oncol. 2025;161:107177.
     PubMed    
     
     
     
404. GIUNCO S, Del Mistro A, Morello M, Lidonnici J, et al
     From infection to immortality: The role of HPV and telomerase in head and neck cancer.
     Oral Oncol. 2025;161:107169.
     PubMed     Abstract available
     
     
     
405. HANNA GJ, Zheng D, Gao W, Hair GM, et al
     PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S.
     Oral Oncol. 2025;161:107146.
     PubMed     Abstract available
     
     
     
406. XU S, He J, Liu Z, Pei Y, et al
     Immune-related adverse events as prognostic biomarkers in recurrent or metastatic nasopharyngeal carcinoma receiving PD-L1 inhibitor: A post-hoc analysis of the multicenter, single-arm, phase 2 study.
     Oral Oncol. 2025;161:107161.
     PubMed     Abstract available
     
     
     December 2024
407. KAOREY N, Dickinson K, Agnihotram VR, Zeitouni A, et al
     The role of ctDNA from liquid biopsy in predicting survival outcomes in HPV-negative head and neck cancer: A meta-analysis.
     Oral Oncol. 2024;161:107148.
     PubMed     Abstract available
     
     
     
408. LIU Y, Fu N, Liu H, Su S, et al
     Corrigendum to "Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations" [160 (2025) 107120/Article:OO_107120].
     Oral Oncol. 2024 Dec 30:107135. doi: 10.1016/j.oraloncology.2024.107135.
     PubMed    
     
     
     
409. DIETRICH N, Watson E, Tadic T, Martino R, et al
     Development of a prediction model for tube feeding dependence in HPV-associated oropharyngeal cancer patients undergoing chemoradiotherapy.
     Oral Oncol. 2024;161:107132.
     PubMed     Abstract available
     
     
     
410. FANG Q, Yuan J, Zhang X, Dai L, et al
     Omitting elective neck dissection in cT1/2N0 oral squamous cell carcinoma with sentinel lymph node metastasis: A prospective study.
     Oral Oncol. 2024;161:107149.
     PubMed     Abstract available
     
     
     
411. PRICE JM, Garcez K, Hughes C, Lee LW, et al
     The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma.
     Oral Oncol. 2024;161:107138.
     PubMed     Abstract available
     
     
     
412. STRUCKMEIER AK, Gosau M, Smeets R
     Immunotherapeutic strategies beyond the PD-1/PD-L1 pathway in head and neck squamous cell carcinoma - A scoping review on current developments in agents targeting TIM-3, TIGIT, LAG-3, and VISTA.
     Oral Oncol. 2024;161:107145.
     PubMed     Abstract available
     
     
     
413. MEGWALU UC, Ma Y, Divi V
     Association of race and ethnicity with quality of care among head and neck cancer patients in California.
     Oral Oncol. 2024;161:107144.
     PubMed     Abstract available
     
     
     
414. PACE GM, Costantino A, De Virgilio A
     Comment on "Surgical, functional, and oncological outcomes of transoral robotic surgery for cT1-T3 supraglottic laryngeal cancers: A systematic review".
     Oral Oncol. 2024;161:107142.
     PubMed    
     
     
     
415. YU ST, Huang D, Xiong C, Xie R, et al
     Selperctinib as neoadjuvant therapy for RET-altered papillary thyroid carcinoma: Two case reports.
     Oral Oncol. 2024;161:107140.
     PubMed     Abstract available
     
     
     
416. ALMEIDA ND, Yu H, Iovoli AJ, Fang M, et al
     Prophylactic gastrostomy tube during chemoradiation for head and neck cancer decreases weight loss but increases rate of tube use beyond six months.
     Oral Oncol. 2024;160:107136.
     PubMed     Abstract available
     
     
     
417. DA MOTA SANTANA LA, Dos Santos Barreto M, Santos GA, Gopalsamy RG, et al
     Comment on "Time to treatment for head and neck cancer patients decreased during the early phase of the COVID-19 pandemic".
     Oral Oncol. 2024;160:107134.
     PubMed    
     
     
     
418. PRACHA SH, Shrestha S, Ryan N, Upadhaya P, et al
     Targeting macrophage migration inhibitory factor to inhibit T cell immunosuppression in the tumor microenvironment and improve cancer outcomes in head and neck squamous cell carcinoma.
     Oral Oncol. 2024;160:107126.
     PubMed     Abstract available
     
     
     
419. LI H, Lou L, Du J, Li M, et al
     Multimodal profiling uncovers tertiary lymphoid structures as a critical determinant of immunotherapy response and prognosis in nasopharyngeal carcinoma.
     Oral Oncol. 2024;160:107129.
     PubMed     Abstract available
     
     
     
420. SANKAR GANESH P, Naseef Pathoor N, Kanna Gopal R
     Letter to the editor regarding, "Impact of post-operative transoral robotic surgery hemorrhage on adjuvant treatment delays in patients with oropharyngeal squamous cell carcinoma".
     Oral Oncol. 2024;159:107091.
     PubMed     Abstract available
     
     
     
421. BALAJI H, Aithal VU, Varghese JJ, Devaraja K, et al
     Agreement between patient-reported and clinician-rated speech and swallowing outcomes - Understanding the trend in post-operative oral cavity cancer patients.
     Oral Oncol. 2024;159:107068.
     PubMed     Abstract available
     
     
     
422. BALAGURU L, Hanubal KS, Galochkina Z, Lee JH, et al
     Surgical and functional outcomes after salvage oropharyngectomy.
     Oral Oncol. 2024;159:107050.
     PubMed     Abstract available
     
     
     
423. KORIC A, Chang CP, Hu S, Snyder J, et al
     Oral health-related quality of life among oropharyngeal cancer survivors.
     Oral Oncol. 2024;159:107062.
     PubMed     Abstract available
     
     
     
424. BOZKURT G, Turri Zanoni M, Ferrari M, Ioppi A, et al
     Salvage surgery in nasopharyngeal Cancer: Unraveling the efficacy of transnasal endoscopic nasopharyngectomy for advanced stage recurrent tumors.
     Oral Oncol. 2024;159:107048.
     PubMed     Abstract available
     
     
     
425. DANIELS KE, Awad DR, Liu SX, Mocharnuk J, et al
     Impact of post-operative transoral robotic surgery hemorrhage on adjuvant treatment delays in patients with oropharyngeal squamous cell carcinoma.
     Oral Oncol. 2024;159:107031.
     PubMed     Abstract available
     
     
     
426. GREEN L, McDowell L, Ip F, Tapia M, et al
     Early return to work is possible after transoral robotic surgery (TORS) in carefully selected patients with oropharyngeal squamous cell carcinoma.
     Oral Oncol. 2024;159:107032.
     PubMed     Abstract available
     
     
     
427. LU YT, Lin CW, Su SC, Ho YT, et al
     L48H37, a curcumin analog, suppresses matrix metalloproteinase-9 expression and activity to hamper nasopharyngeal cancer cell migration.
     Oral Oncol. 2024;159:107038.
     PubMed     Abstract available
     
     
     
428. STAIBANO P, Au M, Xie M, Gupta MK, et al
     Return to work and self-reported swallowing following transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma: A retrospective cohort study.
     Oral Oncol. 2024;159:107033.
     PubMed     Abstract available
     
     
     
429. MORTAJA S, Chiumenti FA, Kalaskar DM, Dwivedi RC, et al
     Surgical complications and functional outcomes of 3191 jejunal free flaps used for reconstruction of circumferential defects following head and neck cancer resections: A systematic review.
     Oral Oncol. 2024;160:107130.
     PubMed     Abstract available
     
     
     November 2024
430. MARRET G, Lamy C, Vacher S, Cabel L, et al
     Deciphering molecular relapse and intra-tumor heterogeneity in non-metastatic resectable head and neck squamous cell carcinoma using circulating tumor DNA.
     Oral Oncol. 2024;160:107111.
     PubMed     Abstract available
     
     
     
431. JEYARAJ G
     Letter to the editor, "Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.".
     Oral Oncol. 2024;160:107092.
     PubMed    
     
     
     
432. LIU Y, Fu N, Liu H, Su S, et al
     Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations.
     Oral Oncol. 2024;160:107120.
     PubMed     Abstract available
     
     
     
433. YAN C, Wang R, Zhang C, Lin G, et al
     Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF.
     Oral Oncol. 2024;160:107119.
     PubMed     Abstract available
     
     
     
434. VON WITZLEBEN A, Grages A, Thomas J, Ezic J, et al
     Immune checkpoint expression on tumor-infiltrating lymphocytes (TIL) is dependent on HPV status in oropharyngeal carcinoma (OPSCC) - A single-cell RNA sequencing analysis.
     Oral Oncol. 2024;159:107107.
     PubMed     Abstract available
     
     
     
435. LI S, Zhao T, Liu N, Li Y, et al
     Global research on oral cancer: A bibliometric analysis based on 82 highly cited publications from 2014 to 2024.
     Oral Oncol. 2024;159:107094.
     PubMed     Abstract available
     
     
     
436. YANG B, Dai X, Li Z, Wu Z, et al
     Noninvasive surface-enhanced Raman spectroscopy outperforms combined positive score in predicting sensitivity to neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
     Oral Oncol. 2024;159:107105.
     PubMed     Abstract available
     
     
     
437. RENGASAMY G, Priya Veeraraghavan V
     Using salivary DNA methylation to predict aging, cell changes, and protein levels for assessing oral mucositis severity and survival in head and neck cancer patients.
     Oral Oncol. 2024;159:107086.
     PubMed    
     
     
     
438. LEE YC, Hsin LJ, Lin WN, Fang TJ, et al
     Robot-assisted versus conventional neck dissection in head and neck cancers: A systematic review and meta-analysis.
     Oral Oncol. 2024;159:107101.
     PubMed     Abstract available
     
     
     
439. MORGENTHALER J, Trommer M, Khor R, Wada M, et al
     Can we safely de-escalate HPV(+) oropharyngeal cancers? - A review of current practices and novel approaches.
     Oral Oncol. 2024;159:107089.
     PubMed     Abstract available
     
     
     
440. LENNON SILVA CUNHA J
     In reply to "Risk of cardiovascular disease among head and neck cancer survivors: A population-based matched cohort study".
     Oral Oncol. 2024;159:107096.
     PubMed    
     
     
     
441. TOPKAN E, Somay E, Ozturk D, Selek U, et al
     Commentary on "Effect analysis of 847 nasopharyngeal carcinoma cases treated with intensity modulated radiation: Experience and suggestions".
     Oral Oncol. 2024;159:107099.
     PubMed    
     
     
     
442. SHANG K, Li T, Chen Y, Luo X, et al
     Gemcitabine plus cisplatin versus docetaxel plus cisplatin and fluorouracil induction chemotherapy combined with locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A single center prospective phase II clinical trial.
     Oral Oncol. 2024;159:107087.
     PubMed     Abstract available
     
     
     
443. COSTANTINO A, Haughey B, Alamoudi U, Magnuson JS, et al
     Challenges in treating oropharyngeal cancer in the elderly: The role of transoral surgery.
     Oral Oncol. 2024;158:106996.
     PubMed    
     
     
     
444. SOLARZ P, Mackiewicz-Nartowicz H, Sinkiewicz A, Burduk P, et al
     Results of CO2 laser surgery in laryngeal papillomatosis.
     Oral Oncol. 2024;158:107004.
     PubMed     Abstract available
     
     
     
445. ASHIQUE S, Houshyari M, Islam A, Pal R, et al
     The role of microbiota in nasopharyngeal cancer: Where do we stand?
     Oral Oncol. 2024;158:106982.
     PubMed     Abstract available
     
     
     
446. DE SENA COSTA DE OLIVEIRA D, Cunha JLS
     Comment on: Salivary DNA methylation derived estimates of biological aging, cellular frequency, and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
     Oral Oncol. 2024;159:107097.
     PubMed    
     
     
     
447. HIMANI
     Letter to the editor: Burden of oral cancer and associated risk factors at national and state levels: A systematic analysis from the global burden of disease in India, 1990-2021.
     Oral Oncol. 2024;159:107093.
     PubMed    
     
     
     October 2024
448. MUTHAMIZH S, Balachandran S, Dilipan E
     Opinion on "Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma".
     Oral Oncol. 2024;159:107095.
     PubMed    
     
     
     
449. LEHYANTI J, Even C, Fessart E, Wagner-Ballon C, et al
     Management of oligometastatic head and neck squamous cell carcinoma: A systematic review.
     Oral Oncol. 2024;159:107085.
     PubMed     Abstract available
     
     
     
450. VILLARME A, Ebran N, Pace-Loscos T, Schiappa R, et al
     Prognostic impact of intra tumoral HPV-16 viral load in oropharyngeal squamous cell carcinomas.
     Oral Oncol. 2024;159:107082.
     PubMed     Abstract available
     
     
     
451. KARAMCHANDANI S, Sahovaler A, Crosbie-Jones E, McGurk M, et al
     Incidence and predictive factors for positive non-sentinel lymph nodes in completion neck dissection following a positive sentinel node biopsy in early oral cancer.
     Oral Oncol. 2024;159:107081.
     PubMed    
     
     
     
452. LI D, Lopez A, Shrivastava N, Chan W, et al
     Comprehensive functional evaluation of head and neck squamous cell carcinoma with BH3-profiling demonstrates apoptotic competency and therapeutic efficacy of BH3-mimetics.
     Oral Oncol. 2024;159:107069.
     PubMed     Abstract available
     
     
     
453. WU WB, Xia L, Feng ZK, Liang JL, et al
     Characteristics and treatment of epistaxis in nasopharyngeal carcinoma.
     Oral Oncol. 2024;159:107071.
     PubMed     Abstract available
     
     
     
454. ZANG Y, Lu Y, Yu J, Dong Q, et al
     FOXP3 inhibits proliferation and migration by competitively inhibiting YAP1 in nasopharyngeal carcinoma.
     Oral Oncol. 2024;159:107066.
     PubMed     Abstract available
     
     
     
455. GARSET-ZAMANI M, Lomholt AF, Charabi BW, Norling R, et al
     Surgeon-performed intraoperative transoral ultrasound improves the detection of human papillomavirus-positive head and neck cancers of unknown primary.
     Oral Oncol. 2024;159:107073.
     PubMed     Abstract available
     
     
     
456. LIU C, Zhao H, Lu Y, Xia Y, et al
     Nomograms to predict occult contralateral central lymph node metastases in unilateral papillary thyroid carcinoma with ipsilateral clinical lymph node metastasis.
     Oral Oncol. 2024;159:107051.
     PubMed     Abstract available
     
     
     
457. SONG Y, Zhang Y, Bai Y, Wang T, et al
     Combination kinase inhibitors and immunotherapy for unresectable anaplastic thyroid carcinoma: A retrospective single-center study.
     Oral Oncol. 2024;159:107067.
     PubMed     Abstract available
     
     
     
458. AWEEDA M, Richard K, Arnaud EH, Divi V, et al
     Factors influencing lymph node yield in head and neck squamous cell carcinoma: A scoping review.
     Oral Oncol. 2024;159:107070.
     PubMed     Abstract available
     
     
     
459. HE SQ, Liu GY, Yu YH, Wang L, et al
     Establishing M1 subdivision for de novo nasopharyngeal carcinoma patients receiving immuno-chemotherapy: A multicenter, retrospective cohort study.
     Oral Oncol. 2024;159:107074.
     PubMed     Abstract available
     
     
     
460. LEE RH, Evans C, Alqasieer Y, Knott PD, et al
     Bite me: Can active biting during trismus therapy improve mouth opening in head and neck cancer patients?
     Oral Oncol. 2024;159:107064.
     PubMed    
     
     
     
461. ZHAO BY, Hirayama S, Goss D, Zhao Y, et al
     Human papillomavirus-associated nasopharyngeal carcinoma: A systematic review and meta-analysis.
     Oral Oncol. 2024;159:107057.
     PubMed     Abstract available
     
     
     
462. TANG WZ, Xu WZ, Liu TH
     Exploring the potential of gemcitabine, capecitabine, and tislelizumab after anti-PD-1 treatment in nasopharyngeal carcinoma.
     Oral Oncol. 2024;159:107065.
     PubMed    
     
     
     
463. YACOUB I, Qian JY, Nashed K, Youssef M, et al
     Radiation techniques and advancements in nasopharyngeal carcinoma.
     Oral Oncol. 2024;159:107060.
     PubMed    
     
     
     
464. GAUDIOSO P, Contro G, Taboni S, Costantino P, et al
     Intraoperative surgical navigation as a precision medicine tool in sinonasal and craniofacial oncologic surgery.
     Oral Oncol. 2024;157:106979.
     PubMed     Abstract available
     
     
     
465. DAWSON A, Karimi AH, Shaikh MH, Gazala W, et al
     Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.
     Oral Oncol. 2024;159:107061.
     PubMed     Abstract available
     
     
     
466. AKASHANAND, Zahiruddin QS, Jena D, Ballal S, et al
     Burden of oral cancer and associated risk factors at national and state levels: A systematic analysis from the global burden of disease in India, 1990-2021.
     Oral Oncol. 2024;159:107063.
     PubMed     Abstract available
     
     
     September 2024
467. LECHIEN JR
     Surgical, Functional, and oncological outcomes of transoral robotic surgery for cT1-T3 supraglottic laryngeal Cancers: A systematic review.
     Oral Oncol. 2024;159:107047.
     PubMed     Abstract available
     
     
     
468. KEEFE K, McCrary HC, Wei M, Mark B, et al
     Risk of cardiovascular disease among head and neck cancer survivors: A population-based matched cohort study.
     Oral Oncol. 2024;159:107041.
     PubMed     Abstract available
     
     
     
469. DHARSHINI RAJATHIRAJAN S
     Commentary on "Salivary DNA methylation derived estimates of biological aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients".
     Oral Oncol. 2024;159:107053.
     PubMed    
     
     
     
470. LYU W, Gong J, Zhu L, Xu T, et al
     MR radiomics unveils neoadjuvant chemo-responsiveness with insights into selective treatment de-intensification in HPV-positive oropharyngeal carcinoma.
     Oral Oncol. 2024;159:107049.
     PubMed     Abstract available
     
     
     
471. PRITHVIRAJ
     Comment on "Sexual Health, sexuality and sexual intimacy in patients with head and neck cancer".
     Oral Oncol. 2024;159:107054.
     PubMed    
     
     
     
472. DINESHKUMAR R
     Letter to the editor: Risk factors associated with ototoxicity in long-term survivors of nasopharyngeal carcinoma.
     Oral Oncol. 2024;159:107052.
     PubMed    
     
     
     
473. VALCENKO A, Zwick A, Schneider L, Linxweiler M, et al
     The tumor cell killing capacity of head and neck cancer patient-derived neutrophils depends on tumor stage, gender and the antibody isotype.
     Oral Oncol. 2024;159:107042.
     PubMed     Abstract available
     
     
     
474. MIN Y, Liu X, Wei Z, Song G, et al
     Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study.
     Oral Oncol. 2024;159:107028.
     PubMed     Abstract available
     
     
     
475. RENGASAMY G, Priya Veeraraghavan V
     Comment on "The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-) radiotherapy".
     Oral Oncol. 2024;159:107035.
     PubMed    
     
     
     
476. DHARSHINI RAJATHIRAJAN S
     Commentary on "Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression.".
     Oral Oncol. 2024;159:107037.
     PubMed    
     
     
     
477. DHARSHINI RAJATHIRAJAN S
     Commentary on "Predictive value of CXCL1(+)_FAP(+) phenotype in CAFs for distant metastasis and its correlation with PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma patients".
     Oral Oncol. 2024;159:107036.
     PubMed    
     
     
     
478. VERSCHOOR CP, Santi SA, Singh R, Tharmalingam S, et al
     Salivary DNA methylation derived estimates of biological aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
     Oral Oncol. 2024;159:107030.
     PubMed     Abstract available
     
     
     
479. PAKA LUBAMBA G, Hua Y, Bao M, Zhang G, et al
     Variant of internal jugular vein reconstruction in bilateral radical neck dissection.
     Oral Oncol. 2024;159:107015.
     PubMed     Abstract available
     
     
     
480. WANG A, Xia H, Li J, Diao P, et al
     Development of a novel prognostic signature derived from super-enhancer-associated gene by machine learning in head and neck squamous cell carcinoma.
     Oral Oncol. 2024;159:107016.
     PubMed     Abstract available
     
     
     
481. PRITHVIRAJ T
     Commentary on "Tumor Habitat-Based MRI features assessing early response in locally advanced nasopharyngeal carcinoma".
     Oral Oncol. 2024;159:107018.
     PubMed    
     
     
     
482. XIAOYU J, Baihong P, Yaozhen L, Shen C, et al
     Preoperative protective stenting of the carotid artery in severe complex head and neck cancer resection.
     Oral Oncol. 2024;158:107012.
     PubMed     Abstract available
     
     
     
483. PAYNE K, Suriyanarayanan H, Brooks J, Mehanna H, et al
     Exploring the impact of intra-tumoural heterogeneity on liquid biopsy cell-free DNA methylation and copy number in head and neck squamous cell carcinoma.
     Oral Oncol. 2024;158:107011.
     PubMed     Abstract available
     
     
     
484. ZHANG X, Zheng W, Huang S, Li H, et al
     Xerostomia prediction in patients with nasopharyngeal carcinoma during radiotherapy using segmental dose distribution in dosiomics and radiomics models.
     Oral Oncol. 2024;158:107000.
     PubMed     Abstract available
     
     
     
485. CHEN J, Cheng H, Liang Y, Lin J, et al
     The efficacy of adjuvant chemotherapy in patients with different midpoint-radiotherapy Epstein-Barr virus DNA plasma loads.
     Oral Oncol. 2024;156:106938.
     PubMed     Abstract available
     
     
     August 2024
486. LECHIEN JR, Hans S
     Survival, Surgical, and functional outcomes of transoral laser microsurgery for cT1-T3 supraglottic laryngeal Cancers: A systematic review.
     Oral Oncol. 2024;158:107009.
     PubMed     Abstract available
     
     
     
487. ZHAO J, Ruan X, Wei S, Zheng X, et al
     The first report of bilateral parapharyngeal lymph node metastasis from papillary thyroid carcinoma: A case report.
     Oral Oncol. 2024;158:107006.
     PubMed    
     
     
     
488. YIN WJ, Mao W, Yang F, Wang MY, et al
     Effect analysis of 847 nasopharyngeal carcinoma cases treated with intensity modulated radiation: Experience and suggestions.
     Oral Oncol. 2024;158:107001.
     PubMed     Abstract available
     
     
     
489. GE Y, Liu H, Huang W, Zhu H, et al
     Immunoinhibitory effects of hypoxia-driven reprogramming of EGR1(hi) and EGR3 positive B cells in the nasopharyngeal carcinoma microenvironment.
     Oral Oncol. 2024;158:106999.
     PubMed     Abstract available
     
     
     
490. T P
     Commentary on "Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/mHNSCC)".
     Oral Oncol. 2024;158:107010.
     PubMed    
     
     
     
491. ZHOU X, Shao T, Jia H, Hou L, et al
     Current state, challenges, and future perspective of adaptive radiotherapy: A narrative review of nasopharyngeal carcinoma.
     Oral Oncol. 2024;158:107008.
     PubMed     Abstract available
     
     
     
492. PRASAD M
     DNA Methylation Mediated Epigenetic Silencing of PD-1 and PD-L1: Therapeutic Implications in Oral Cancer.
     Oral Oncol. 2024 Aug 23:106995. doi: 10.1016/j.oraloncology.2024.106995.
     PubMed    
     
     
     
493. KNAP RABJERG H, Grau Eriksen J, Soby S
     Impact of antibiotics on PD-1 inhibition in recurrent/metastatic head and neck squamous cell carcinoma.
     Oral Oncol. 2024;158:107003.
     PubMed    
     
     
     
494. DU F, Shao K, Yang Y, Bai X, et al
     Comparative dosimetric analysis of normal brain tissue in patients with Nasopharyngeal carcinoma at different stages after radiation therapy.
     Oral Oncol. 2024;158:106998.
     PubMed     Abstract available
     
     
     
495. ALSHEIKH S, Su J, O'Sullivan B, Ringash J, et al
     The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-)radiotherapy.
     Oral Oncol. 2024;158:107007.
     PubMed     Abstract available
     
     
     
496. SUN L, Cohen RB, Dimitrios Colevas A
     Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC).
     Oral Oncol. 2024;158:106997.
     PubMed     Abstract available
     
     
     
497. HANNA GJ, Jabalee J, Lukens JN, Sun L, et al
     Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer.
     Oral Oncol. 2024;158:107002.
     PubMed     Abstract available
     
     
     
498. YUAN J, Wu M, Qiu L, Xu W, et al
     Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma.
     Oral Oncol. 2024;158:106980.
     PubMed     Abstract available
     
     
     
499. YANG R, Li R, Niu X, Zhao Y, et al
     Gemcitabine, capecitabine, and tislelizumab in recurrent/metastatic nasopharyngeal carcinoma following prior anti-PD-1 therapy failure: A retrospective study.
     Oral Oncol. 2024;158:106981.
     PubMed     Abstract available
     
     
     
500. HUSSEIN NI, Molina AH, Sunga GM, Amit M, et al
     Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders.
     Oral Oncol. 2024;158:106986.
     PubMed     Abstract available
     
     
     
501. PAN GS, Sun XM, Kong FF, Wang JZ, et al
     Delta magnetic resonance imaging radiomics features?based nomogram predicts long?term efficacy after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
     Oral Oncol. 2024;157:106987.
     PubMed     Abstract available
     
     
     
502. QIN G, Liao X, Zhang B, Su Y, et al
     An individualized immune prognostic signature in nasopharyngeal carcinoma.
     Oral Oncol. 2024;157:106985.
     PubMed     Abstract available
     
     
     
503. TAMIOLAKIS P, Shah A, Dawson R, Ramasamy S, et al
     HPV- associated sinonasal squamous cell carcinoma with FGFR3::TACC3 fusion. A rare case report.
     Oral Oncol. 2024;157:106983.
     PubMed     Abstract available
     
     
     
504. SHIMIZU H, Kodaira T, Kiyota N, Hayashi R, et al
     Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008.
     Oral Oncol. 2024;157:106976.
     PubMed     Abstract available
     
     
     
505. SANKAR S
     Letter to editor regarding "Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression".
     Oral Oncol. 2024;157:106977.
     PubMed    
     
     
     
506. SCHAEFFERS AWMA, Scholten HA, van Beers MA, Meussen BW, et al
     The effect of skeletal muscle mass on dose-limiting toxicities during (chemo)radiotherapy in patients with head and neck cancer: A systematic review and meta-analysis.
     Oral Oncol. 2024;157:106978.
     PubMed     Abstract available
     
     
     July 2024
507. MCDOWELL L, Gough K, White I, Corry J, et al
     Sexual Health, sexuality and sexual intimacy in patients with head and neck cancer - A narrative review.
     Oral Oncol. 2024;157:106975.
     PubMed     Abstract available
     
     
     
508. DAS S, Ghosh Laskar S, V Kane S, D'Cruz AK, et al
     Adjuvant therapy for intermediate risk factors in oral cancer: Can we reach a consensus?
     Oral Oncol. 2024;157:106972.
     PubMed     Abstract available
     
     
     
509. JEYARAJ G
     Letter to the editor, "Clinical benefits of combining oral cytotoxic chemotherapeutic agents with radiotherapy in patients with T2N0 glottic squamous cell carcinoma based on the reports of the head and neck Cancer Registry of Japan.".
     Oral Oncol. 2024;157:106974.
     PubMed    
     
     
     
510. JEYARAJ G
     Letter to the editor, "Mutation detection in saliva from oral cancer patients".
     Oral Oncol. 2024;157:106929.
     PubMed    
     
     
     
511. GANESH PS, Pathoor NN, Gopal RK
     Letter to the editor regarding "Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis.
     Oral Oncol. 2024;157:106954.
     PubMed     Abstract available
     
     
     
512. LORINI L, Zigliani G, Morbini P, Salviato E, et al
     Expression of PDL-1 between primary and recurrent/metastatic head and neck squamous cell carcinoma: A bi-institutional retrospective concordance analysis (CONCORDL-1 study).
     Oral Oncol. 2024;157:106950.
     PubMed     Abstract available
     
     
     
513. JEYACHANDRAN S
     Comment on, "Characterization of oral microbiota in HPV and non-HPV head and neck squamous cell carcinoma and its association with patient outcomes".
     Oral Oncol. 2024;157:106973.
     PubMed     Abstract available
     
     
     
514. SURESH S
     Comment on: An algorithm for standardization of tumor infiltrating lymphocyte evaluation in head and neck cancers.
     Oral Oncol. 2024;157:106959.
     PubMed    
     
     
     
515. WEN YF, Huang WJ, Chen XL, Cai HT, et al
     Predictive value of CXCL1(+)_FAP(+) phenotype in CAFs for distant metastasis and its correlation with PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma patients.
     Oral Oncol. 2024;157:106963.
     PubMed     Abstract available
     
     
     
516. ICHISAKA T, Sano D, Kijima N, Kawakita D, et al
     Clinical benefits of combining oral cytotoxic chemotherapeutic agents with radiotherapy in patients with T2N0 glottic squamous cell carcinoma based on the reports of the Head and Neck Cancer Registry of Japan.
     Oral Oncol. 2024;157:106942.
     PubMed     Abstract available
     
     
     
517. TINO R, Roach MA, Fuentes GD, Agrawal A, et al
     Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy.
     Oral Oncol. 2024;157:106944.
     PubMed     Abstract available
     
     
     
518. LIM CY, Ng GWY, Goh CK, Lee MKC, et al
     Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression.
     Oral Oncol. 2024;157:106941.
     PubMed     Abstract available
     
     
     
519. SHANMUGAM G
     Letter to the editor, "The prognostic value of pretreatment (18)F-FDG PET-CT parameters with peripheral blood markers in patients with de novo metastatic nasopharyngeal carcinoma.".
     Oral Oncol. 2024;157:106951.
     PubMed    
     
     
     
520. MEIVELU MOOVENDHAN
     "Letter to the Editor: Next-Generation sequencing (NGS) profiling of matched tumor and Circulating Tumor DNA (ctDNA) in Head and Neck Squamous Cell Carcinoma (HNSCC)".
     Oral Oncol. 2024;157:106940.
     PubMed    
     
     
     
521. ZENGA J, Himburg HA, Wong SJ, Kearl T, et al
     In silico identification of public neo-antigens in head and neck Cancer for T cell receptor Engineering: Targeting PI3KCA and TP53 missense mutations.
     Oral Oncol. 2024 Jul 14:106947. doi: 10.1016/j.oraloncology.2024.106947.
     PubMed    
     
     
     
522. DHARMALINGAM JOTHINATHAN MK
     Letter to the Editor, "Immunochemotherapy alone or immunochemotherapy plus subsequent locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma".
     Oral Oncol. 2024;156:106948.
     PubMed    
     
     
     
523. SHANMUGAM G
     Commentary on, "Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma.".
     Oral Oncol. 2024;156:106952.
     PubMed    
     
     
     
524. PIYARATHNE NS, Liyanage SN, Rasnayaka RMSGK, Hettiarachchi PVKS, et al
     A comprehensive dataset of annotated oral cavity images for diagnosis of oral cancer and oral potentially malignant disorders.
     Oral Oncol. 2024;156:106946.
     PubMed     Abstract available
     
     
     
525. MAHDI AGM
     Knowledge, and attitude of medical students about role of human papilloma virus, and vaccine in head and neck cancer.
     Oral Oncol. 2024;156:106939.
     PubMed     Abstract available
     
     
     
526. SHANMUGAM G
     Letter to the editor, "Letter to the editor, "Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study.".
     Oral Oncol. 2024;156:106935.
     PubMed    
     
     
     
527. ARUMUGANAINAR D, Sekaran S
     Correspondence on "Global burdens of nasopharyngeal carcinoma in children and young adults: Trends and predictions to 2040".
     Oral Oncol. 2024;156:106933.
     PubMed    
     
     
     
528. GU LW, Zhang X, Zhang J, Xiao BB, et al
     The prognostic value of pretreatment (18)F-FDG PET-CT parameters with peripheral blood markers in patients with de novo metastatic nasopharyngeal carcinoma.
     Oral Oncol. 2024;156:106928.
     PubMed     Abstract available
     
     
     
529. SURESH S
     Commentary on 'Mutation detection in saliva from oral cancer patients'.
     Oral Oncol. 2024;156:106937.
     PubMed    
     
     
     
530. KASIRAJAN H, Rengasamy G, Priya Veeraraghavan V
     Comment on the "Quality of life in 583 head and neck cancer survivors assessed with the FACE-Q head and neck cancer module".
     Oral Oncol. 2024;156:106934.
     PubMed    
     
     
     
531. KANNAN R
     Comments on: Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence?
     Oral Oncol. 2024;156:106936.
     PubMed    
     
     
     
532. DAUNGSUPAWONG H, Wiwanitkit V
     Letter to the Editor on "Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance".
     Oral Oncol. 2024;156:106930.
     PubMed    
     
     
     
533. LIOKATIS P, Liokati I, Obermeier K, Smolka W, et al
     Prognostic role of lymph node micrometastasis in oral and oropharyngeal cancer: A systematic review.
     Oral Oncol. 2024;154:106808.
     PubMed     Abstract available
     
     
     
534. CHEN AM
     Translational risk-adapted approaches to de-escalated radiation for human papillomavirus-positive oropharyngeal cancer: Past, present, and future.
     Oral Oncol. 2024;154:106850.
     PubMed     Abstract available
     
     
     
535. SATHISHKUMAR K
     Letter to the editor "risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial ".
     Oral Oncol. 2024;156:106931.
     PubMed    
     
     
     
536. HARIDEVAMUTHU B
     Letter to the Editor: "Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell Carcinoma".
     Oral Oncol. 2024;156:106913.
     PubMed    
     
     
     June 2024
537. BENJAMIN WJ, Feng AL, Heft Neal M, Bellile E, et al
     Utility of bioselection with neoadjuvant chemotherapy for organ preservation in patients with T4 laryngeal cancer.
     Oral Oncol. 2024;156:106917.
     PubMed     Abstract available
     
     
     
538. ZHAO X, Zhou Y, Peng G, Wen L, et al
     Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma.
     Oral Oncol. 2024;156:106918.
     PubMed     Abstract available
     
     
     
539. SARAVANAN M, Singh Carmelin D, Mohanprasanth A, Arockiaraj J, et al
     Comment on "Oral microbiome and risk of incident head and neck cancer: A nested case-control study".
     Oral Oncol. 2024;156:106911.
     PubMed    
     
     
     
540. POONGAVANAM SS, Behera A, Dharmalingam Jothinathan MK
     Letter to the editor, "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer".
     Oral Oncol. 2024;156:106912.
     PubMed    
     
     
     
541. JEYARAJ G
     Letter to the editor, "Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer".
     Oral Oncol. 2024;156:106906.
     PubMed    
     
     
     
542. DONG S, Bei W, Lin L, Jiang Y, et al
     Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study.
     Oral Oncol. 2024;156:106908.
     PubMed     Abstract available
     
     
     
543. JEYARAJ G
     Transformative impact of 3D-Printed implants and Virtual surgical planning in oral cancer reconstruction.
     Oral Oncol. 2024;156:106896.
     PubMed    
     
     
     
544. SHANMUGAM G
     Letter to the editor, "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer.".
     Oral Oncol. 2024;156:106915.
     PubMed    
     
     
     
545. BASTIEN AJ, Ng J, Cong I, Garcia J, et al
     Patient perceptions underlying ctDNA molecular surveillance for HPV(+) oropharyngeal squamous cell carcinoma.
     Oral Oncol. 2024;156:106894.
     PubMed     Abstract available
     
     
     
546. HARIDEVAMUTHU B
     Letter to the Editor: "Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral Cancer".
     Oral Oncol. 2024;155:106902.
     PubMed    
     
     
     
547. MEIVELU MOOVENDHAN
     Letter to the editor, "Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma".
     Oral Oncol. 2024;155:106903.
     PubMed    
     
     
     
548. PRASAD M, Sekar R, Murugan R
     Letter to editor on "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer".
     Oral Oncol. 2024;155:106899.
     PubMed    
     
     
     
549. SELVI POONGAVANAM S, Behera A, Kumar Dharmalingam Jothinathan M
     Letter to the Editor, "The predictive role of PD-L1 in head and neck Cancer: A systematic review and Meta-Analysis".
     Oral Oncol. 2024;155:106904.
     PubMed    
     
     
     
550. TOPKAN E, Somay E, Bascil S, Selek U, et al
     Comment on prospective comparison of acute severe toxicities between smokers and non-smokers during radiotherapy for head and neck cancers.
     Oral Oncol. 2024;155:106898.
     PubMed    
     
     
     
551. HARIDEVAMUTHU B
     Genomic instability in HPV-positive oropharyngeal squamous cell carcinoma: The role of integration sites in treatment response.
     Oral Oncol. 2024;155:106895.
     PubMed    
     
     
     
552. LEI S, Chen L, Ji P, Li K, et al
     Global burdens of nasopharyngeal carcinoma in children and young adults and predictions to 2040.
     Oral Oncol. 2024;155:106891.
     PubMed     Abstract available
     
     
     
553. DA MOTA SANTANA LA, Simoes JMD, Santos GA, Gopalsamy RG, et al
     Comment on "Association between COVID 19 exposure and expression of malignant pathological features in oral cancer: A retrospective cohort study".
     Oral Oncol. 2024;155:106877.
     PubMed    
     
     
     
554. ROOF SA, Jabalee J, Rettig EM, Chennareddy S, et al
     Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance.
     Oral Oncol. 2024;155:106874.
     PubMed     Abstract available
     
     
     
555. FERRARI M, Mularoni F, Taboni S, Crosetti E, et al
     Corrigendum to "How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? a multi-institutional study on 366 patients from the ARYFIX collaborative group" [Oral Oncol. 152C (2024) 106744].
     Oral Oncol. 2024 Jun 8:106887. doi: 10.1016/j.oraloncology.2024.106887.
     PubMed    
     
     
     
556. PRASAD M, Murugan R
     Comment on "The circadian clock gene, BMAL1, promotes radiosensitization in nasopharyngeal carcinoma by inhibiting the epithelial-to-mesenchymal transition via the TGF-beta1/Smads/Snail1 axis".
     Oral Oncol. 2024;155:106890.
     PubMed    
     
     
     
557. TASOULAS J, Adams GJ, Schrank TP, Agala CB, et al
     Time to treatment for head and neck cancer patients decreased during the early phase of the Covid-19 pandemic.
     Oral Oncol. 2024;155:106879.
     PubMed    
     
     
     
558. DHARMALINGAM JOTHINATHAN MK
     Letter to the Editor, "How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? A multi-institutional study on 366 patients from the ARYFIX collaborative group".
     Oral Oncol. 2024;155:106878.
     PubMed    
     
     
     
559. BABU S, Krishnan M
     Human papillomavirus and oropharyngeal cancer in HNSCC: A growing concern.
     Oral Oncol. 2024;153:106824.
     PubMed    
     
     
     
560. PACE GM, Costantino A, Festa BM, Spriano G, et al
     Oropharyngeal squamous cell carcinoma: Treatment (de-) intensification?
     Oral Oncol. 2024;153:106299.
     PubMed    
     
     
     
561. LU HA, Wang YM, Chih Chen W, Wu CN, et al
     Post-irradiation dysbiosis in patients with nasopharyngeal carcinoma having received radiotherapy - A pilot study.
     Oral Oncol. 2024;154:106864.
     PubMed     Abstract available
     
     
     
562. KRC R, Mendes W, Molitoris J, Ferris M, et al
     Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer.
     Oral Oncol. 2024;154:106875.
     PubMed     Abstract available
     
     
     May 2024
563. XU W, Qiu L, Li F, Fei Y, et al
     Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis.
     Oral Oncol. 2024;154:106865.
     PubMed     Abstract available
     
     
     
564. IMAMURA Y, Kiyota N, Tahara M, Kodaira T, et al
     Risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial.
     Oral Oncol. 2024;154:106868.
     PubMed     Abstract available
     
     
     
565. PARK R, Li J, Slebos RJC, Chaudhary R, et al
     Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
     Oral Oncol. 2024;154:106866.
     PubMed     Abstract available
     
     
     
566. SARAVANAN M, Carmelin DS, Mohanprasanth A, Arockiaraj J, et al
     Comment on "Oral microbiome and risk of incident head and neck cancer: A nested case-control study".
     Oral Oncol. 2024;154:106858.
     PubMed    
     
     
     
567. HESHAM A, David Kim D, Alshamrani Y, AlOtaibi F, et al
     The efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy in recurrent head and neck squamous cell carcinoma. Report of a case and review of the literature.
     Oral Oncol. 2024;154:106863.
     PubMed    
     
     
     
568. ABBACI M, Villard A, Auperin A, Asmandar S, et al
     Ultra-fast confocal fluorescence microscopy for neck lymph node imaging in head and neck cancer.
     Oral Oncol. 2024;154:106862.
     PubMed     Abstract available
     
     
     
569. YAO Y, Ouyang Q, Wang S, Li K, et al
     Incorporation of PD-1 blockade into induction chemotherapy improved tumor response in patients with locoregionally advanced nasopharyngeal carcinoma in a retrospective patient cohort.
     Oral Oncol. 2024;154:106867.
     PubMed     Abstract available
     
     
     
570. RICARDO ELIAS DE MELO P, Agra Monteiro M, Vitoria de Araujo Lopes N, Silva Cunha JL, et al
     In response to the reply on 'Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes'.
     Oral Oncol. 2024;154:106856.
     PubMed    
     
     
     
571. COSTANTINO A, Haughey B, Zhu J, Mekhail T, et al
     Sinonasal squamous cell carcinoma in the United States: Temporal and geographic patterns associated with HPV testing and positivity.
     Oral Oncol. 2024;154:106855.
     PubMed     Abstract available
     
     
     
572. PEZZULLA D, Re A, Ferro M, Cilla S, et al
     Lower cranial nerve palsy after hypofractionated radiotherapy in a laryngeal cancer patient: A letter to the editor.
     Oral Oncol. 2024;154:106837.
     PubMed    
     
     
     
573. ALVES DA MOTA SANTANA L, Gois Floresta L, Maciel Alves EV, Ribeiro Couto G, et al
     Reply to: Comment on "Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes".
     Oral Oncol. 2024;154:106840.
     PubMed    
     
     
     
574. HE S, Yu H, He L, Liu M, et al
     Risk factors associated with ototoxicity in long-term nasopharyngeal carcinoma survivors.
     Oral Oncol. 2024;154:106827.
     PubMed     Abstract available
     
     
     
575. VAZQUEZ FL, Coracin FL, Arantes KLBF, Ferigatto JL, et al
     An oral cancer screening program in Brazil: Analysis of seven years of outcome after its implementation in the suburban cities of Sao Paulo.
     Oral Oncol. 2024;154:106826.
     PubMed     Abstract available
     
     
     
576. DE FELICE F, Guerrero Urbano T
     Lower-neck sparing in patients with uninvolved neck nasopharyngeal carcinoma: Unquestioned benefit?
     Oral Oncol. 2024;154:106836.
     PubMed    
     
     
     
577. HAN N, Zhou D, Ruan M, Yan M, et al
     Corrigendum to "Cancer cell-derived extracellular vesicles drive pre-metastatic niche formation of lymph node via IFNGR1/JAK1/STAT1-activated-PD-L1 expression on FRCs in head and neck cancer" [Oral Oncol. 145 (2023) 106524].
     Oral Oncol. 2024 May 9:106831. doi: 10.1016/j.oraloncology.2024.106831.
     PubMed    
     
     
     
578. INVERNIZZI C, Da Silva Ribeiro Mota A, Barbe C, Bouazzi L, et al
     Prospective comparison of acute severe toxicities between smokers and non-smokers during radiotherapy for head and neck cancers.
     Oral Oncol. 2024;153:106833.
     PubMed     Abstract available
     
     
     
579. PADERNO A, Petrelli F, Lorini L, Capriotti V, et al
     The predictive role of PD-L1 in head and neck cancer: A systematic review and meta-analysis.
     Oral Oncol. 2024;153:106799.
     PubMed     Abstract available
     
     
     
580. LIU Y, Zuo ZC, Zeng XY, Ma J, et al
     Establishing subdivisions of M1 stage nasopharyngeal carcinoma based on decision tree classification: A multicenter retrospective study.
     Oral Oncol. 2024;153:106834.
     PubMed     Abstract available
     
     
     
581. XU Y, Xu T, Yao Q, Chen J, et al
     Individualized radiology screening for newly diagnosed nasopharyngeal carcinoma.
     Oral Oncol. 2024;153:106828.
     PubMed     Abstract available
     
     
     
582. ALMANGUSH A, Makitie AA, Leivo I
     Assessment of tumor-infiltrating lymphocytes in head and neck cancer: Clinical scenarios.
     Oral Oncol. 2024;153:106829.
     PubMed    
     
     
     
583. DAS R, Misra SR
     Author's reply to comment on "awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?".
     Oral Oncol. 2024;153:106832.
     PubMed    
     
     
     
584. DHARMALINGAM JOTHINATHAN MK
     Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020.
     Oral Oncol. 2024;152:106811.
     PubMed    
     
     
     
585. POOJARI M, Madabhavi I, Desai S
     Extraskeletal Ewing's sarcoma of supraglottis: A rare case report.
     Oral Oncol. 2024;152:106789.
     PubMed     Abstract available
     
     
     
586. MELDGAARD JUSTESEN M, Kronberg Jakobsen K, Fenger Carlander AL, Hjordt Holm Larsen M, et al
     Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020.
     Oral Oncol. 2024;152:106783.
     PubMed     Abstract available
     
     
     April 2024
587. TONSBEEK AM, Hundepool CA, Roubos J, Rijken B, et al
     Quality of life in 583 head and neck cancer survivors assessed with the FACE-Q head and neck cancer module.
     Oral Oncol. 2024;153:106813.
     PubMed     Abstract available
     
     
     
588. MICHIKAWA C, Gleber-Netto FO, Pickering CR, Rao X, et al
     Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer.
     Oral Oncol. 2024;153:106729.
     PubMed     Abstract available
     
     
     
589. FANG Q, Yuan J, Zhang X, Dai L, et al
     Oncologic and functional results between sentinel lymph node biopsy and elective neck dissection in cT1/2N0 maxillary squamous cell carcinoma.
     Oral Oncol. 2024;152:106810.
     PubMed     Abstract available
     
     
     
590. YEO BSY, Lee RS, Lim NE, Tan E, et al
     Efficacy and Safety of Cell-based Immunotherapy in The Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma - A Systematic Review and Meta-analysis.
     Oral Oncol. 2024;152:106786.
     PubMed     Abstract available
     
     
     
591. LI Y, Zhou Y, Zhao C, Liu L, et al
     The circadian clock gene, BMAL1, promotes radiosensitization in nasopharyngeal carcinoma by inhibiting the epithelial-to-mesenchymal transition via the TGF-beta1/Smads/Snail1 axis.
     Oral Oncol. 2024;152:106798.
     PubMed     Abstract available
     
     
     
592. RAMASAMY P, Sekaran S, Ganapathy D
     Oral cancer burden in tribal populations residing in India.
     Oral Oncol. 2024;152:106801.
     PubMed    
     
     
     
593. SEKAR D
     Comment on betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
     Oral Oncol. 2024;152:106800.
     PubMed    
     
     
     
594. SARAVANAN M
     Comment on "Nanomedicine, an emerging therapeutic strategy for oral cancer therapy".
     Oral Oncol. 2024;152:106806.
     PubMed    
     
     
     
595. RICARDO ELIAS DE MELO P, Agra Monteiro M, Henrique Rocha Aragao H, Vitoria de Araujo Lopes N, et al
     Comment on "Awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?".
     Oral Oncol. 2024;152:106802.
     PubMed    
     
     
     
596. SMITH JD, Heft-Neal ME, Rosko AJ, Chepeha DB, et al
     Upfront neck dissection to guide single-modality therapy for early stage supraglottic squamous cell carcinoma.
     Oral Oncol. 2024;152:106803.
     PubMed    
     
     
     
597. KONO M, Saito S, Rokugo M, Egloff AM, et al
     Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
     Oral Oncol. 2024;152:106795.
     PubMed     Abstract available
     
     
     
598. SEGNA E, Civita F, Denaro N, Beltramini GA, et al
     Cavernous sinus metastasis in head and neck cancer: Focus on oral squamous cell cancer.
     Oral Oncol. 2024;152:106784.
     PubMed     Abstract available
     
     
     
599. SIVAPERUMAL P, Ganapathy D, Kamala K
     Revolutionizing oral cancer treatment: Harnessing the potential of adaptive CARneg T cell therapy.
     Oral Oncol. 2024;152:106794.
     PubMed    
     
     
     
600. RAJAKUMAR HK, Coimbatore Sathyabal V, Vivekanandam A, Nasrin Jabarulla K, et al
     Evaluation of nuclear morphometry in exfoliative cytology of buccal mucosa in patients with high risk of oral cancer.
     Oral Oncol. 2024;152:106793.
     PubMed     Abstract available
     
     
     
601. SARAVANAN M
     Comment on "The microbiome and oral cancer: More questions than answers".
     Oral Oncol. 2024;152:106792.
     PubMed    
     
     
     
602. ARAGAO HHR, Monteiro MA, Lopes NVA, Cunha JLS, et al
     Comment on "Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study".
     Oral Oncol. 2024;152:106788.
     PubMed    
     
     
     
603. DAS R, Misra SR, Nayak A
     Awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?
     Oral Oncol. 2024;152:106790.
     PubMed    
     
     
     
604. XIAO X, Shi Z, Song Z
     Comment on circulatory mitochondrial DNA as a novel biomarker for head and neck cancers.
     Oral Oncol. 2024;152:106785.
     PubMed    
     
     
     
605. GASNE C, Atallah S, Dauzier E, Thariat J, et al
     Twelve years after: The french national network on rare head and neck tumours (REFCOR).
     Oral Oncol. 2024;151:106762.
     PubMed     Abstract available
     
     
     
606. MALI SB
     Role of telemedicine in head neck cancer.
     Oral Oncol. 2024;151:106746.
     PubMed     Abstract available
     
     
     
607. MIRIMOGHADDAM M, Bohlouli B, Lai H, Viegas S, et al
     Trends and predictors of unplanned hospitalization among oral and oropharyngeal cancer patients; an 8-year population-based study.
     Oral Oncol. 2024;151:106742.
     PubMed     Abstract available
     
     
     March 2024
608. MEGAHED R, Prabhu AV, Mack DP, Gholami S, et al
     Re-irradiation of recurrent head and neck cancers using pulsed reduced dose rate radiotherapy: An institutional series.
     Oral Oncol. 2024;152:106778.
     PubMed     Abstract available
     
     
     
609. LORINI L, Gili R, Salvestrini V, Morelli I, et al
     De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control "always" matter?
     Oral Oncol. 2024;152:106768.
     PubMed     Abstract available
     
     
     
610. XIROU V, Moutafi M, Bai Y, Nwe Aung T, et al
     An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers.
     Oral Oncol. 2024;152:106750.
     PubMed     Abstract available
     
     
     
611. HONG RL, Yen CJ, Lien MY, Cheng R, et al
     Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
     Oral Oncol. 2024;152:106760.
     PubMed     Abstract available
     
     
     
612. FERRARI M, Mularoni F, Taboni S, Crosetti E, et al
     How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? a multi-institutional study on 366 patients from the ARYFIX collaborative group.
     Oral Oncol. 2024;152:106744.
     PubMed     Abstract available
     
     
     
613. TOYA R, Fukugawa Y, Saito T, Matsuyama T, et al
     Radiation Therapy Oncology Group 8502 "QUAD shot" regimen using volumetric modulated arc therapy for incurable head and neck cancer.
     Oral Oncol. 2024;151:106752.
     PubMed     Abstract available
     
     
     
614. RUIZ-TORRES DA, Naegele S, Podury A, Wirth L, et al
     Immunotherapy time of infusion impacts survival in head and neck cancer: A propensity score matched analysis.
     Oral Oncol. 2024;151:106761.
     PubMed     Abstract available
     
     
     
615. SIMON L, Paly J, Park E, Samuels-Kalow M, et al
     Medicare dental coverage for patients with head and neck cancer: An opportunity in need of advocates.
     Oral Oncol. 2024 Mar 15:106754. doi: 10.1016/j.oraloncology.2024.106754.
     PubMed    
     
     
     
616. RICARDO ELIAS DE MELO P, Agra Monteiro M, Vitoria de Araujo Lopes N, Silva Cunha JL, et al
     Comment on "advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with Teledentistry for Better Patient Outcomes".
     Oral Oncol. 2024;151:106758.
     PubMed    
     
     
     
617. RAJANATHADURAI J, Sindya J, Madar IH, Perumal E, et al
     Exosomal immune checkpoint protein (PD-L1): Hidden player in PD-1/PD-L1 blockade immunotherapy resistance in oral cancer.
     Oral Oncol. 2024;151:106748.
     PubMed    
     
     
     
618. ZUPANCIC M, Kostopoulou ON, Holzhauser S, Lukoseviciute M, et al
     Human papillomavirus (HPV) load is higher in HPVDNA/p16 positive than in HPVDNA positive/p16 negative oropharyngeal squamous cell carcinoma but does not differ significantly between various subsites or correlate to survival.
     Oral Oncol. 2024;151:106749.
     PubMed     Abstract available
     
     
     
619. FERRARO T, Pershad AR, Arora S, Lee E, et al
     The utility of ultrasonographic surveillance in management of a presumed branchial cleft cyst later confirmed HPV-associated oropharyngeal cancer.
     Oral Oncol. 2024;151:106743.
     PubMed     Abstract available
     
     
     
620. KIM DH, Lim ST, Kim HR, Kang EJ, et al
     Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study.
     Oral Oncol. 2024;151:106739.
     PubMed     Abstract available
     
     
     
621. SANTANA LADM, Floresta LG, Alves EVM, Melo LMR, et al
     Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes.
     Oral Oncol. 2024;151:106741.
     PubMed    
     
     
     
622. CHEN K, Shi M, Mo S, Liu T, et al
     Clinical features and prognostic factors of nasopharyngeal carcinoma with brain metastases.
     Oral Oncol. 2024;151:106738.
     PubMed     Abstract available
     
     
     
623. DING C, Dai DY, Luo ZK, Wang GY, et al
     Evaluation of a novel model incorporating serological indicators into the conventional TNM staging system for nasopharyngeal carcinoma.
     Oral Oncol. 2024;151:106725.
     PubMed     Abstract available
     
     
     
624. LU X, Zhang JL, Zhai X, Liu Q, et al
     A case report on a nasal and oral cavity involving large solitary fibrous tumor and comprehensive review of case literature.
     Oral Oncol. 2024;150:106715.
     PubMed     Abstract available
     
     
     
625. YOUNG RJ, Angel C, Bressel M, Pizzolla A, et al
     Characterising B cell expression and prognostic significance in human papillomavirus positive oropharyngeal cancer.
     Oral Oncol. 2024;150:106687.
     PubMed     Abstract available
     
     
     February 2024
626. VAN SCHAIK JE, van der Vegt B, Slagter-Menkema L, van der Laan BFAM, et al
     Identification of new head and neck squamous cell carcinoma molecular imaging targets.
     Oral Oncol. 2024;151:106736.
     PubMed     Abstract available
     
     
     
627. MELACHURI M, Kurukulasuriya C, Rumde P, Patel T, et al
     Treatment package time < 14 weeks improves recurrence free and disease specific survival in HPV positive OPC with high-risk features.
     Oral Oncol. 2024;151:106703.
     PubMed     Abstract available
     
     
     
628. AHMED AA, Sborchia M, Bye H, Roman-Escorza M, et al
     Mutation detection in saliva from oral cancer patients.
     Oral Oncol. 2024;151:106717.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Otorhinolaryngology is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum